1	The putative drug efflux systems of the Bacillus cereus group
2	Karl A. Hassan ^{1†} , Annette Fagerlund ^{2†§} , Liam D.H. Elbourne ¹ , Aniko Vörös ² , Jasmin K.
3	Kroeger ^{2,3} Roger Simm ² [^] , Nicolas J. Tourasse ² [¶] , Sarah Finke ^{2,4} , Peter J.F. Henderson ⁵ , Ole
4	Andreas Økstad ^{2,4} , Ian T. Paulsen ^{1*} , Anne-Brit Kolstø ^{2,4*}
5	1. Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney,
6	NSW, Australia
7	2. Laboratory for Microbial Dynamics (LaMDa), Section for Pharmaceutical Biosciences,
8	School of Pharmacy, University of Oslo, Oslo, Norway
9	3. Institut für Pharmazeutische Biologie und Biotechnologie, Albert-Ludwigs Universität,
10	Freiburg, Germany
11	4. Centre for Integrative Microbial Evolution (CIME), Faculty of Mathematics and Natural
12	Sciences, University of Oslo, 0316 Oslo, Norway
13	5. School of BioMedical Sciences and Astbury Centre for Structural Molecular Biology,
14	University of Leeds, Leeds, UK
15	† These authors contributed equally to this work.
16	* Correspondence: Prof. Anne-Brit Kolstø, a.b.kolsto@farmasi.uio.no; Prof. Ian Paulsen,
17	ian.paulsen@mq.edu.au.
18	§ Present address: Nofima, PB210, 1431 Ås, Norway
19	^ Present address: Norwegian Veterinary Institute, PB 750 Sentrum, 0106 Oslo, Norway
20	¶ Present address: ARNA Laboratory, INSERM U1212, CNRS UMR5320, Université
21	Bordeaux 2; 146 rue Léo-Saignat, 33076 Bordeaux, France
22	Short title: Efflux systems of the Bacillus cereus group

23 Abstract

The Bacillus cereus group of bacteria includes seven closely related species, three of which, 24 B. anthracis, B. cereus and B. thuringiensis, are pathogens of humans, animals and/or insects. 25 Preliminary investigations into the transport capabilities of different bacterial lineages 26 suggested that genes encoding putative efflux systems were unusually abundant in the B. 27 *cereus* group compared to other bacteria. To explore the drug efflux potential of the *B. cereus* 28 group all putative efflux systems were identified in the genomes of prototypical strains of B. 29 cereus, B. anthracis and B. thuringiensis using our Transporter Automated Annotation 30 31 Pipeline. More than 90 putative drug efflux systems were found within each of these strains, accounting for up to 2.7% of their protein coding potential. Comparative analyses 32 demonstrated that the efflux systems are highly conserved between these species; 70-80% of 33 34 the putative efflux pumps were shared between all three strains studied. Furthermore, 82% of the putative efflux system proteins encoded by the prototypical *B. cereus* strain ATCC 14579 35 (type strain) were found to be conserved in at least 80% of 169 B. cereus group strains that 36 have high quality genome sequences available. However, only a handful of these efflux 37 pumps have been functionally characterized. Deletion of individual efflux pump genes from 38 39 *B. cereus* typically had little impact to drug resistance phenotypes or the general fitness of the strains, possibly because of the large numbers of alternative efflux systems that may have 40 overlapping substrate specificities. Therefore, to gain insight into the possible transport 41 functions of efflux systems in B. cereus, we undertook large-scale qRT-PCR analyses of 42 efflux pump gene expression following drug shocks and other stress treatments. Clustering of 43 gene expression changes identified several groups of similarly regulated systems that may 44 45 have overlapping drug resistance functions. In this article we review current knowledge of the small molecule efflux pumps encoded by the *B. cereus* group and suggest the likely functions 46 of numerous uncharacterised pumps. 47

48 Introduction

The Bacillus cereus group is composed of seven species of low G+C Gram-positive 49 spore-forming bacteria, which based on 16S rRNA sequence data form a separate cluster in 50 the phylogenetic tree of *Bacillaceae* and Firmicutes [1]. The *B. cereus* group includes *B.* 51 cereus (sensu stricto), B. anthracis, and B. thuringiensis, which are all well studied and are 52 pathogens of animals, humans or insects, as well as B. weihenstephanensis, B. mycoides, B. 53 pseudomycoides and B. cytotoxicus. The different species can commonly, but with variable 54 frequency, be found in the soil environment, and can thus constitute polluter organisms in 55 food production facilities and dairies, as well as in hospitals [2,3]. Bacteria within the B. 56 cereus group have also been suggested to naturally inhabit the insect gut [4]. 57

The pathogenic species of the *B. cereus* group have different host preferences, mainly 58 due to traits encoded on plasmids. B. anthracis is the cause of anthrax, primarily an animal 59 60 disease but also occasionally of humans, due to its production of anthrax-specific toxins (lethal and edema toxins) and a poly- γ -D-glutamate capsule which provides protection against 61 the host immune system. B. anthracis is endemic in several parts of the world [5]. The three 62 toxin genes (pag, lef and cya) are located on a plasmid, pXO1 (189 kb), while the genes 63 necessary for capsule synthesis, capABC, are located on plasmid pXO2 (95 kb), and fully 64 65 virulent B. anthracis strains carry both plasmids. B. cereus sensu stricto (here called B. cereus) is an opportunistic pathogen capable of causing a range of diseases [2,6], most 66 prominently foodborne disease due to the production of enterotoxins (diarrhoeal syndrome) or 67 68 a non-ribosomally synthesized dodecadepsipeptide toxin (emetic syndrome). The emetic toxin is encoded by genes on a large 270 kb plasmid, pCER270 [7,8]. Interestingly, B. cereus 69 strains causing anthrax-like disease were isolated from welders in the US and shown to carry 70 a plasmid highly similar to pXO1 [9], as well as from African great apes (Cameroon, Ivory 71

Coast), shown to carry full pXO1 and pXO2 virulence plasmids [10,11]. B. thuringiensis 72 73 strains produce proteinaceous crystal toxins (Cry or Cyt toxin) during sporulation which are the primary cause of their toxicity toward insects, and which are encoded by genes most often 74 located on plasmids. B. thuringiensis strains do however, also carry the chromosomal 75 enterotoxin genes found in B. cereus, and the two species are genetically indistinguishable 76 based on chromosomal characters [12,13]. Many of the chromosomally encoded virulence 77 factors in *B. cereus* and *B. thuringiensis* are positively regulated at the transcriptional level by 78 the PlcR-PapR peptide-based quorum sensing system. The *plcR* gene is also present in *B*. 79 anthracis strains, but carries a deleterious mutation making the protein non-functional and 80 81 leaving the PlcR regulated genes non-transcribed [14].

82 Given that different species within the *B. cereus* group have diverse toxic effects and host specificities, but are closely related at the phylogenetic level, their intra- and inter-species 83 diversity has frequently been studied at the genome level. Large-scale sequencing studies of 84 85 B. cereus group strains have allowed the calculation of a core genome of genes shared between all strains (aproximately 1750 genes), and a set of additional genes found in almost 86 every genome, constituting the extended core (approximately 2150 genes) [15]. The B. cereus 87 group core genome appears to harbour a high number of genes encoding transporter proteins. 88 This may reflect the fact that *B. cereus* group bacteria are frequently found in environments 89 90 such as soil, which display high variability with respect to potential nutrients and exposure to toxic chemicals, including antibiotics and other antimicrobial agents. Putative efflux pumps 91 appear to be particularly common within the genomes of the *B. cereus* group but relatively 92 few of these transporters have been functionally characterised to date. In contrast, Bacillus 93 subtilis encodes some of the best characterised multidrug efflux pumps in bacteria, including 94 the related Bmr and Blt transporters from the major facilitator superfamily [16-18]. 95

Bacterial drug efflux pumps generally fall into one of five families or superfamilies of 96 transport proteins, the major facilitator superfamily (MFS), the ATP binding cassette (ABC) 97 superfamily, the resistance/nodulation/division (RND) superfamily, the multidrug and toxic 98 compound extrusion (MATE) family and the small multidrug resistance superfamily (SMR). 99 A sixth family of multidrug efflux pumps, the Proteobacterial antimicrobial compound 100 extrusion (PACE) family was recently identified [19,20]. However, genes encoding PACE 101 102 family proteins have been identified in the genome sequences of a small number of species outside the Proteobacteria. 103

Here we describe the putative efflux pumps carried by *B. cereus* group isolates that fall within each of the five major families of transport proteins. The number of pumps, their putative substrates and conservation across the group is described, followed by a detailed review of the efflux systems encoded by the *B. cereus* type strain, ATCC 14579. The transcriptional responses of selected pumps encoded by this strain to a panel of structurally and mechanistically diverse drugs or stress conditions were determined to gain insight into their potential functional roles.

112 Methods

Bioinformatics analyses

Transport proteins encoded within the genomes of B. cereus ATCC 14579, B. 114 anthracis Ames and B. thuringiensis konkukian 97-27, were identified using the Transporter 115 Automated Annotation Pipeline (TransAAP) [21]. This pipeline predicts the complete 116 complement of transporters encoded by an organism based on the annotated amino acid 117 sequences within its genome sequence by running a variety of searches including BLASTP (to 118 the Transporter Classification Database - TCDB, TransAAP and GenBank databases), HMM, 119 Pfam, TIGRfam HMM and COG searches, as well as other analyses such as TMHMM 120 hydropathy prediction [21]. Efflux proteins were identified in the TransAAP output and 121 manually curated for a likely role in the efflux of drugs or small molecules. 122

To broadly examine the conservation of putative efflux systems between the *B. cereus* 123 type strain ATCC 14579 and other strains within the B. cereus group, we conducted 124 reciprocal best-match BLASTP 2.2.28+ analyses. Searches between all CDSs annotated in the 125 ATCC 14579 genome and 168 other B. cereus group strains listed in the RefSeq database 126 with assembly level "complete" or "chromosome" (August 2016; S1 Table) were executed 127 through the Proteinortho tool [22]. Putative orthologs/paralogs were identified as reciprocal 128 best-match BLASTP hits that recorded an e-value below 1e-50, and greater than 50% 129 coverage. 130

131 Antimicrobial exposure, stress treatments and RNA isolation

Minimum inhibitory concentrations (MIC) towards *B. cereus* ATCC 14579 for chloramphenicol, kanamycin, erythromycin, tetracycline, and ethidium bromide were previously determined [23], and MIC values for norfloxacin, 2,2'-dipyridyl, tannic acid, Dominulin B and a crude ethanol surface extract of a social paper wasp, *Polistes humilis* [24],
were determined using the same method.

137 MH broth was inoculated with a 1% inoculum of an overnight culture of B. cereus ATCC 14579 and grown at 30°C with shaking to an OD₆₀₀ of approximately 0.8. The culture 138 was then diluted in MH broth to OD₆₀₀=0.1, and grown as before to an OD₆₀₀ of 139 approximately 0.8. The culture was then split and the compound (or crude wasp ethanol 140 extract) used for antimicrobial exposure treatment was added at a concentration equivalent to 141 50% of the respective MIC to separate cultures. An untreated culture was included as a 142 control. The cultures were further grown for 20 minutes. Bacterial cells were harvested by 143 incubating cultures in an equal volume of ice-cold methanol for 5 minutes before 144 145 centrifugation at 4000 x g for 5 minutes. Pellets were stored at -80°C.

For extraction of RNA, cells were lysed using Lysing Matrix B and a FastPrep instrument (both MP Biomedicals), and RNA was isolated using the PureLink RNA Mini Kit (Invitrogen) or the RNeasy Mini Kit (Qiagen). RNA was treated with TURBO DNase (Ambion) as described, followed by a second round of purification using one of the RNA Mini Kits. RNA concentration and purity were measured using a NanoDrop ND-1000 spectrophotometer.

152 **Quantitative reverse transcription PCR (qRT-PCR)**

153 cDNA synthesis was performed in duplicate for each RNA sample, using the 154 SuperScript VILO cDNA Synthesis Kit (Invitrogen) or the Quantitect cDNA synthesis Kit 155 (QIAGEN) and respective protocols, with 1 μ g RNA. qPCR reactions were performed on a 156 MasterCycler realplex⁴ (Eppendorf) in a 96-well microtiterplate format and a final volume of 157 5 μ l using 1 μ l cDNA diluted 1:20, 2.5 μ l 2×GoTaq qPCR master mix (Promega) and 0.2 μ M of 158 each primer. In qPCR experiments studying gene expression in cells exposed to wasp ethanol extract or Dominulin B, qPCR was performed in 200 ul thin-walled tubes and a final volume of 10 μ l, using 5.0 μ l 2×GoTaq qPCR master mix. Cycling conditions were 95 °C for 2 minutes followed by 40 cycles at 95 °C for 10 seconds, 55 °C for 10 seconds, and 68 °C for 8 seconds, followed by a melting curve analysis, which resulted in single product specific melting temperatures for all samples. Control qPCR reactions using DNase-treated RNA diluted to 0.005 μ g/ μ l as the template confirmed the absence of amplification of contaminating DNA.

166 The BC1744 helicase gene was selected for use as the reference gene. The list of primers used is given in S2 Table. For gene expression analysis, the quantification cycle (Cq) 167 values determined using the realplex software (Eppendorf). Cq values were transformed into 168 linear scale expression quantities using the formula E^{Cq} [25]. The expression of each target 169 gene was normalized to that obtained for the helicase reference gene reaction run on the same 170 plate. Then, for each target gene, the expression ratio between the untreated and antimicrobial 171 treated samples was calculated ($\Delta\Delta$ -Cq-method) [25] and finally the values obtained for the 172 two technical replicates were averaged. 173

Biofilm formation

The biofilm forming capabilities of B. cereus ATCC 14579 wild type and isogenic 175 markerless gene deletion mutant strains were investigated with a microplate screening assay 176 modified from a previously described method [26]. Precultures were grown in Y1 minimal 177 medium [27] at 30 °C to early exponential growth (optical density at 600 nm (OD₆₀₀) ~ 0.3) 178 and were then used to inoculate fresh Y1 medium to an OD₆₀₀ of 0.01. For each strain, sixteen 179 wells of a 96-well polystyrene microplate (Corning[®] 3788) were filled with 125 µl of the 180 bacterial suspension. The plates were produced in duplicate and each plate contained eight 181 wells of Y1 medium as a negative control. Following incubation at 20 °C for 48 h and 72 h, 182

respectively, the wells of each microplate were washed once with phosphate-buffered saline (PBS) and stained with a 0.1 % (w/v) aqueous solution of methyl violet 6B for 30 min at room temperature. Wells were then washed three times with PBS and dried upside down over night. To quantify biofilm formation the dye was solubilized by incubating the wells with 150 μ l of a 1:4 acetone/ethanol mixture for 10 min at room temperature, and subsequently absorbance at 570 nm was determined.

190 Results and Discussion

Putative drug efflux systems are highly represented and well conserved in the *Bacillus cereus* group

To define the efflux potential of the *B. cereus* group, putative efflux systems were 193 identified in the complete genome sequences of three reference strains, B. cereus ATCC 194 14579, B. anthracis Ames and B. thuringiensis konkukian 97-27, using the transporter 195 automated annotation pipeline (TransAAP) [21]. These analyses identified 93, 93 and 103 196 197 putative efflux systems in these strains, respectively (Table 1). Remarkably, these efflux systems account for 2.3 to 2.7 % of the predicted protein coding potential in these strains 198 (Table 1). The majority of the efflux systems identified were classified within the MFS 199 (greater than 50 pumps in all three strains) or ABC superfamily (28 to 35 transport systems), 200 with only 3 to 5 efflux pumps from each of the RND, MATE and SMR (super)families (Table 201 1). For comparison, the numbers of putative efflux pumps encoded within the genomes of 202 other bacterial strains within the Firmicutes were determined; Bacillus subtilis 168, 203 Staphylococcus aureus N315 and Clostridium perfringens 13 (Table 1). Each of these strains 204 205 encoded less than half the number of putative efflux pumps identified in the *B. cereus* group isolates, and these pumps accounted for only 1.1 to 1.5 % of the predicted protein coding 206 potential of the strains (Table 1). These results suggest that strains in the *B. cereus* group have 207 208 exceptional drug and/or small molecule efflux potential.

210 Table 1. Numbers of putative drug efflux systems encoded in the genomes of reference

Strain	ABC	MFS	MATE	SMR	RND	Total ^b	% ORFs
Bacillus anthracis Ames	28^{a}	51	4	5	4	93	2.3
Bacillus cereus ATCC 14579	28	53	4	4	3	93	2.3
<i>Bacillus thuringensis</i> konkukian 97-27	35	53	4	5	5	103	2.7
Bacillus subtilis 168	3	32	4	2	1	42	1.1
Staphylococcus aureus N315	7	21	1	1	1	31	1.4
Clostridium perfringens 13	12	7	11	0	0	30	1.5

211 strains of the *B. cereus* group, and other Firmicutes.

212 *a*. Transporters were identified using the Transporter Automated Annotation Pipeline and are213 listed at www.membranetransport.org.

b. Total number of transport systems. Some ABC and SMR (super)family systems arecomprised of several proteins, see Tables 3 and 5 for details.

216

To examine the level of conservation of the putative efflux systems in B. cereus 217 ATCC 14579, B. anthracis Ames and B. thuringiensis konkukian 97-27, their predicted 218 219 proteomes were compared using reciprocal best-match BLASTP searches. These searches suggested that 75 of the putative efflux systems were conserved in all three strains, 220 representing 81 % of those encoded in the B. anthracis Ames and B. cereus ATCC 14579 221 genomes (Fig 1A). To further explore the conservation of efflux systems in the B. cereus 222 group, we examined the level of conservation of the *B. cereus* ATCC 14579 efflux pumps in 223 224 168 other B. cereus group strains with available high-quality genome sequences (S1 Table). This analysis suggested that 21 putative efflux proteins encoded by B. cereus ATCC 14579 225 were conserved in all 168 strains (Fig 1B). Furthermore, 82 % of the putative efflux system 226 proteins in B. cereus ATCC 14579 were conserved in at least 80 % of the strains examined 227 (Fig 1B). These highly conserved putative efflux pumps are likely to have important core 228 functions, possibly related to the basic physiology of the cell. The most poorly conserved 229 230 transport systems were classified within the MFS or ABC superfamily (Fig 1B). However as

231 mentioned above there are large numbers of these transporters encoded in *B. cereus* group232 genomes.

233

234 Fig 1. Conservation of putative efflux systems encoded in the *Bacillus cereus* group. (A) Venn diagram showing conservation of putative efflux systems in fully sequenced 235 representatives of the *B. cereus* group. (B) Conservation of genes encoding efflux system 236 components in B. cereus ATCC 14579. Reciprocal BLASTP 2.2.28+ searches (as executed 237 through the Proteinortho tool [22]) of the B. cereus ATCC 14579 predicted proteome with 238 168 other strains in the B. cereus group (S1 Table) were used to determine the level of 239 conservation. Each transporter component is represented by a single box, the size and shading 240 241 of which corresponds to its conservation. Panel B was generated using TreeMap version 4.1.

242

Major facilitator superfamily efflux pumps encoded in *B. cereus*ATCC 14579

The major facilitator superfamily (MFS) of transport proteins is an ancient protein 245 family found in all classes of living organisms. MFS proteins participate in a broad range of 246 transport reactions including the uptake of essential nutrients and the efflux of toxic 247 compounds. Uptake and efflux pumps can be differentiated based on the presence of several 248 key amino acid sequence motifs [28], such as sequence motif C which may be involved in the 249 proton:substrate antiport coupling reaction [29]. The majority of bacterial drug efflux pumps 250 251 classified within the MFS, are found within one of three transporter families, the drug:H⁺ antiport (DHA) 1-3 families, however, several other families are known or predicted to 252 include drug efflux pumps. Proteins classified within the DHA1 and DHA3 families are 253 254 typically organised into 12 transmembrane segments, similar to the majority of MFS pumps, whereas, those within the DHA2 family are typically organised into 14 transmembrane segments. DHA1 and DHA2 family protein sequences are more common in sequence databases and are encoded by both Gram-positive and Gram-negative bacteria, whereas, DHA3 family proteins are principally encoded by Gram-positives.

The genome of B. cereus ATCC 14579 encodes 53 putative MFS family drug efflux 259 pumps. Thirty-eight of these transporters were predicted to fall within the DHA1, DHA2 or 260 DHA3 families, 16, 12 and 10 proteins, respectively, based on BLASTP comparisons to all 261 262 MFS proteins within the TCDB [30] (Table 2). The best hits for the remaining 15 putative B. cereus MFS efflux pumps were to three of the unknown major facilitator families (UMF2, 263 UMF5 and UMF11), the nickel resistance (Nre) family, the putative aromatic compound/drug 264 265 exporter (ACDE) family and the acriflavin-sensitivity (YnfM) family. Transporters within 266 each of these families are known or predicted to function in the efflux of antimicrobial drugs.

Several MFS drug resistance efflux pumps have been previously characterised in *B*. 267 cereus, including two members of the DHA2 family. The first of these, RZC03923 268 269 (orthologous to BC0962 in ATCC 14579) was cloned from B. cereus BRL1244, is similar to LmrB in B. subtilis and was characterised as part of a study examining the homologous 270 DHA2 pump MdeA in S. aureus [31]. This pump was shown to confer resistance to 271 virginiamycin, erythromycin, and lincomycin [31]. The second DHA2 family pump from B. 272 cereus to be examined functionally, BC4707 from B. cereus ATCC 14579, was identified due 273 274 to its increased expression in response to bile salts [32] and was found to facilitate resistance to norfloxacin, kanamycin and ciprofloxacin, and thus functions as a multidrug efflux pump 275 [23]. In addition to the DHA2 family, a recent study by Kroeger et al. (2015) demonstrated 276 that BC3310 encodes an active efflux pump that confers resistance to ethidium bromide, SDS 277 and silver nitrate [33]. The BC3310 pump is the first protein from the UMF2 family of the 278

- 279 MFS to have been studied experimentally, and its resistance phenotypes confirmed that
- 280 members of the UMF2 family function in drug efflux [33].

Conser Best match name Function(s) of best match Top blastp hit(s)^{b,c} Locus tag vation^a 2.A.1.2 - The Drug:H+ Antiporter-1 (12 Spanner) (DHA1) Family BC0855* 97.6 Blt of Bacillus subtilis Multidrug (and spermidine) efflux P39843 2.A.1.2.8 (0); P33449 2.A.1.2.70 (6e-133); P0A0J7 2.A.1.2.10 (3e-95) BC4738 100.0 YttB of *Bacillus subtilis* Unknown O34546 2.A.1.2.69 (4e-152): P0A0J7 2.A.1.2.10 (4e-10): O48658 2.A.1.2.5 (3e-06) BC5012 99.4 PbuE of *Bacillus subtilis* Purine base/nucleoside efflux O797E3 2.A.1.2.25 (8e-130); P77389 2.A.1.2.65 (1e-40); O9S3J9 2.A.1.2.18 (5e-34) BC1786* 97.0 MdtG of Escherichia coli Putative multidrug efflux P25744 2.A.1.2.20 (1e-122); P0A4K4 2.A.1.2.34 (7e-95); O07282 2.A.1.2.75 (8e-18) BC2402 TetA42 of Micrococcus sp. SMCC Tetracycline resistance B2YGG2 2.A.1.2.41 (4e-72); P02982 2.A.1.2.4 (9e-52); O5JAK9 2.A.1.2.39 (1e-49) 42.6 G8878 BC3393 YdhP of Escherichia coli Unknown P77389 2.A.1.2.65 (1e-70); Q797E3 2.A.1.2.25 (3e-57); P23910 2.A.1.2.14 (7e-54) 82.8 BC5058 98.2 YdhP of *Escherichia coli* Unknown P77389 2.A.1.2.65 (3e-70): O797E3 2.A.1.2.25 (2e-57): P23910 2.A.1.2.14 (5e-55) BC3456 95.3 EmrD-3 of *Vibrio cholerae* Multidrug efflux O9KMO3 2.A.1.2.42 (1e-65); P32482 2.A.1.2.3 (4e-26); O7VW14 2.A.1.2.27 (2e-24) BC0204 96.4 Bcr of *Escherichia coli* Multidrug (and L-cysteine) efflux P28246 2.A.1.2.7 (4e-65): O7VW14 2.A.1.2.27 (7e-39): P37597 2.A.1.2.62 (5e-37) BC0860 87.6 LmrP of Lactococcus lactis Multidrug efflux Q48658 2.A.1.2.5 (8e-55); Q34546 2.A.1.2.69 (2e-15); P69367 2.A.1.2.21 (3e-15) BC0256* YdeE of *Escherichia coli* Peptide (and possibly arabinose) P31126 2.A.1.2.55 (2e-20): B8GFY3 2.A.1.46.4 (1e-20) 98.2 exporter BC0667* 98.2 TetA41 of Serratia marcescens Tetracycline exporter Q5JAK9 2.A.1.2.39 (2e-17); Q56RY7 2.A.1.2.38 (2e-16); C2UR80 2.A.1.46.5 (1e-14) BC3622 YdeE of Escherichia coli Peptide (and possibly arabinose) P31126 2.A.1.2.55 (5e-22); O34546 2.A.1.2.69 (7e-14); P69367 2.A.1.2.21 (2e-13) 51.5 exporter BC2885 TetA42 of *Micrococcus* sp. SMCC Tetracycline resistance B2YGG2 **2.A.1.2.41** (5e-12): O8NRB5 **2.A.1.2.24** (1e-12): P31126 **2.A.1.2.55** (3e-11) 98.8 G8878 BC0202 994 PmrA of Streptococcus pneumoniae Multidrug efflux P0A4K4 2.A.1.2.34 (5e-09); P25744 2.A.1.2.20 (1e-07); H6LDK2 2.A.1.2.90 (1e-06) BC2061 HsMDR of Halobacterium sp. Multidrug resistance O9HS33 2.A.1.2.47 (5e-06) 3.6 NRC-1 2.A.1.3 - The Drug:H+ Antiporter-2 (14 Spanner) (DHA2) Family BC4000* Bmr3 of Bacillus subtilis Multidrug resistance P96712 2.A.1.3.50 (0); O32182 2.A.1.3.33 (1e-104); O9ZGB6 2.A.1.3.32 (9e-72) 98.8 BC2880 98.2 Bmr3 of Bacillus subtilis Multidrug resistance P96712 2.A.1.3.50 (0); O32182 2.A.1.3.33 (6e-101); Q9ZGB6 2.A.1.3.32 (5e-66) BC0658 99.4 MdtP of Bacillus subtilis Multidrug efflux O32182 2.A.1.3.33 (0); P96712 2.A.1.3.50 (6e-95); Q9ZGB6 2.A.1.3.32 (1e-82) BC0962 93.5 LmrB of *Bacillus subtilis* Lincomvcin resistance O35018 2.A.1.3.30 (2e-164): O7A3S4 2.A.1.3.61 (6e-109): O5HE38 2.A.1.3.39 (7e-99) BC3212* 95.9 LmrB of *Bacillus subtilis* Lincomvcin resistance O35018 2.A.1.3.30 (6e-132); O7A3S4 2.A.1.3.61 (7e-117); O5HE38 2.A.1.3.39 (4e-111) BC4568* LmrB of *Bacillus subtilis* Lincomycin resistance 98.2 O35018 2.A.1.3.30 (2e-106); O5HE38 2.A.1.3.39 (4e-103); O7A384 2.A.1.3.61 (7e-93) BC0757 95.9 YvmA of *Bacillus subtilis* Unknown O34307 2.A.1.3.56 (3e-100); P37597 2.A.1.2.62 (8e-26); O31762 2.A.1.32.2 (3e-22) BC4707* Bmr3 of Bacillus subtilis Multidrug resistance 98.8 P96712 2.A.1.3.50 (2e-82); O32182 2.A.1.3.33 (9e-80); Q9ZGB6 2.A.1.3.32 (1e-64) BC1757 46.2 EmrB of *Escherichia coli* Multidrug efflux POAEJ0 2.A.1.3.2 (9e-45); O32182 2.A.1.3.33 (1e-44); O9RO29 2.A.1.3.20 (1e-42) BC2310 HsrA of Escherichia coli P31474 2.A.1.3.51 (4e-53); O32182 2.A.1.3.33 (2e-47); O35018 2.A.1.3.30 (3e-44) 98.2 Unknown BC4497 79.3 TetA(L) of Bacillus subtilis Me2+ tetracycline:2H+ antiporter P23054 2.A.1.3.16 (3e-46); P02983 2.A.1.3.6 (7e-42); Q5PU79 2.A.1.3.22 (8e-25) BC3349 91.1 MdtH of *Escherichia coli* Norfloxacin/enoxacin resistance P69367 2.A.1.2.21 (9e-30); O34546 2.A.1.2.69 (7e-11); P0A0J7 2.A.1.2.10 (2e-11) 2.A.1.21 - The Drug:H+ Antiporter-3 (12 Spanner) (DHA3) Family

281 Table 2. Putative *B. cereus* ATCC 14579 MFS efflux pumps

BC205 98.2 YibB of Bacillus subtils Unknown O31600 2x.1.21.3 (5e-32) BC1621 82.8 TIGR0000 of Bacillus clausii Putative macrolide exporter O31137 2.A.1213 (4e-23); C3WVU9 2.A.162.3 (4e-17); ObE7C5 2.A.138.2 (1e-16) BC473 84.0 TeV of Mycobacterium smegmatis Tetracycline resistance O31137 2.A.123 (1e-23); (05161 2.A.1313 (6e-37); OME7C5 2.A.138.2 (1e-16) BC411 83.4 MeEf of Speritococcus progeneous Metroide efflux Q1BKK4 2.A.121 (2e-23); P9527 2.A.131.3 (1e-20); (255937 2.A.132.1 (1e-20); BC444 98.2 TeV of Mycobacterium smegmatis Tetracycline resistance O31137 2.A.121.4 (1e-21); (03161 2.A.131.3 (1e-20); (255937 2.A.132.1 (1e-20); BC444 98.2 TeV of Mycobacterium smegmatis Tetracycline resistance O31187 2.A.121.4 (1e-21); (03161 2.A.131.3 (2e-17); (09X42 2.A.13.1 (1e-20); BC4255 MER Sortier of Stacobococcus progenes Macrolide efflux P95827 2.A.121.1 (1e-08); Q7BKK4 2.A.13.1 (1e-41); (255937 2.A.13.2 (1e-20); BC325 12 MeEA of Streptococcus progenes Macrolide efflux P95827 2.A.121.4 (1e-41); (255937 2.A.123.2 (1e-20); BC3304 99.4 YRU of Bacillus subtilis Possible drug exporter O34929 2.A.1.36.2 (2e-120); P21503 2.A.123.6 (1e-30);	BC5071	39.6	MefE of Streptococcus pneumoniae	Macrolide efflux	Q7BKK4 2.A.1.21.22 (8e-52); P95827 2.A.1.21.1 (1e-50); O31561 2.A.1.31.3 (1e-19)
BC1753 84.0 TetV of Mycobacterium snegmatis Tetraxycline resistance O31137 2.A.1213 (d=25): C3WVU9 2.A.1622 (4=17); Q0F7C 5.A.133.2 (1=c17) BC2421 83.4 MelE of Streptococcus pneumoniae Macrolide efflux Q7BKK4 2.A.121.21 (d=21); O31561 2.A.131.3 (d=27); Q3WVU9 2.A.162.2 (3=20) BC3515 MFS porter of Stackebrandia Unkown D30871 2.A.121.3 (d=21); O31561 2.A.131.3 (d=27); Q3WXU9 2.A.162.2 (3=20) BC434* 98.2 TetV of Mycobacterium snegmatis Tetraxycline resistance O31137 2.A.121.3 (d=21); O31561 2.A.131.3 (d=27); Q3WXU9 2.A.162.2 (3=23) BC434* 98.2 TetV of Mycobacterium snegmatis Tetraxycline resistance O31137 2.A.121.9 (d=7); QVXX44 2.A.130.1 (4=14); Q31561 2.A.131.3 (d=27); Q3WX42 2.A.130.1 (4=13); Q55937 2.A.131.2 (3=13) BC3255 MFS Of Streptococcus progenes Macrolide efflux P95827 2.A.121.1 (1=08); Q7BKK4 2.A.121.22 (9=07) 2.A.136 - The Unknown Major Facilitator-2 (UME2) Family D03804 effug exporter O34929 2.A.136.2 (2=126); Q1503 2.A.126.1 (7=16); Q568Y7 2.A.12.38 (1=09) 2.A.131 - The Nickel Resistance (Nre) Family Kurstakin/surfactin Q3160 2.A.131.4 (0); O31561 2.A.131.3 (4=38); O31137 2.A.121.2 (2=21) BC3300* 90.4 Y1K for Bacillus subtilis Unkown O31561 2.A.131.3 (1=27); G3W	BC2055	98.2		Unknown	
BC1753 84.0 TetV of Mycobacterium snegmatis Tetraxycline resistance O31137 2.A.1213 (d=25): C3WVU9 2.A.1622 (4=17); Q0F7C 5.A.133.2 (1=c17) BC2421 83.4 MelE of Streptococcus pneumoniae Macrolide efflux Q7BKK4 2.A.121.21 (d=21); O31561 2.A.131.3 (d=27); Q3WVU9 2.A.162.2 (3=20) BC3515 MFS porter of Stackebrandia Unkown D30871 2.A.121.3 (d=21); O31561 2.A.131.3 (d=27); Q3WXU9 2.A.162.2 (3=20) BC434* 98.2 TetV of Mycobacterium snegmatis Tetraxycline resistance O31137 2.A.121.3 (d=21); O31561 2.A.131.3 (d=27); Q3WXU9 2.A.162.2 (3=23) BC434* 98.2 TetV of Mycobacterium snegmatis Tetraxycline resistance O31137 2.A.121.9 (d=7); QVXX44 2.A.130.1 (4=14); Q31561 2.A.131.3 (d=27); Q3WX42 2.A.130.1 (4=13); Q55937 2.A.131.2 (3=13) BC3255 MFS Of Streptococcus progenes Macrolide efflux P95827 2.A.121.1 (1=08); Q7BKK4 2.A.121.22 (9=07) 2.A.136 - The Unknown Major Facilitator-2 (UME2) Family D03804 effug exporter O34929 2.A.136.2 (2=126); Q1503 2.A.126.1 (7=16); Q568Y7 2.A.12.38 (1=09) 2.A.131 - The Nickel Resistance (Nre) Family Kurstakin/surfactin Q3160 2.A.131.4 (0); O31561 2.A.131.3 (4=38); O31137 2.A.121.2 (2=21) BC3300* 90.4 Y1K for Bacillus subtilis Unkown O31561 2.A.131.3 (1=27); G3W	BC1621	82.8	TIGR00900 of Bacillus clausii	Putative macrolide exporter	Q5WAS7 2.A.1.21.8 (6e-32); O31561 2.A.1.31.3 (2e-28); P39642 2.A.1.21.5 (2e-18)
BC429 96.4 TetV of Mycobacterium smegmatis Tetracycline resistance 031172.A.1.21.3 (1e-23); 031561 2.A.1.31.3 (0e-17); ASYZ14 2.A.1.62.3 (2e-20) BC2115 MFS porter of Stackebrandia Unknown D30871 2.A.1.21.2 (2e-23); P95872.A.1.21.1 (5e-21); C3WU9 2.A.16.2 (3e-20) BC1325 MFS porter of Stackebrandia Unknown D30871 2.A.1.21.3 (4e-19); O31561 2.A.1.31.3 (2e-17); O9X4X4 2.A.1.30.1 (3e-13) BC3255 MFS carrier of Thermoplasma Unknown Q9HLP1 2.A.1.21.3 (4e-19); O31561 2.A.1.31.3 (2e-17); O9X4X4 2.A.1.30.1 (3e-13) BC3255 1.2 MetA of Streptococcus progenes Macrolide efflux P9587 2.A.1.21.1 (1e-08); Q7BKK4 2.A.1.21.2 (9e-07) 2.A.1.26 - The Unknown Mujor Facilitators - 2UMF2 / Barnity Possible drug exporter O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) 2.A.1.26 - The Unknown Mujor Facilitators - 2UMF2 / Barnity Possible drug exporter O34929 2.A.1.36.2 (2e-106); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) 2.A.1.26 - The Nicke Resistance (Ner P Barnity VTFF of Bacillus subilis Nuknown O31561 2.A.1.31.3 (1e-38); O31137 2.A.1.21.3 (7e-15) BC2804 97.6 NFIS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-17); O3WU9 2.A.1.62.2 (1e-24); O7BKK4 2.A.1.21.22 (2e-14) BC2819 97.6 NFIS of Bacillus subilis U	BC1753	84.0	TetV of Mycobacterium smegmatis	Tetracycline resistance	
BC2515 MES porter of Stackebrandtia Unknown D3Q871 2.A.1.21.1 (4e-21); O31561 2.A.1.31.3 (1e-20); Q55937 2.A.1.31.2 (1e-20) BC0434* 98.2 TeV of Mycobacterium smegmatis Tetracycline resistance O31137 2.A.1.21.3 (4e-19); O31561 2.A.1.31.3 (2e-17); O9X4X4 2.A.1.30.1 (3e-13) BC325 MFS caridophilum O91HLP1 2.A.1.21.9 (3e-17); O9X4X4 2.A.1.30.1 (4e-14); O55937 2.A.1.31.2 (3e-13) BC325 L2 MeK of Streptococcus progenes Macrolide eflux P95827 2.A.1.21.1 (1e-08); Q7BKK4 2.A.1.21.22 (9e-07) 2.A.1.26.T tenkhown Major Facilitator-2 (UMF2) Family Possible drug exporter O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) 2.A.1.31 The Nickel Resistance (Nrc) Family BC2450 Kurstakin/surfactin exporter 42.0 KEs for Bacillus subtilts Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (2e-14) BC2390 97.6 YfiS of Bacillus subtilts Unknown O31561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-24); Q7BKK4 2.A.1.21.2 (2e-14) BC2390 97.6 YfiS of Bacillus subtilts Unknown O31561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-24); Q7BKK4 2.A.1.21.2	BC4929	96.4	TetV of Mycobacterium smegmatis	Tetracycline resistance	
63.9 nassauensis Control Mycobacterium smegmatis Control Mycobacterium smegmatis BC0434* 98.2 TetV of Mycobacterium smegmatis Tetracycline resistance 031137 2.A.I.21.3 (4e-19); 031561 2.A.I.31.3 (2e-17); 09X4X4 2.A.I.30.1 (3e-13) BC3225 MFS carrier of Thermoplasma Unknown 09HLP1 2.A.I.21.9 (3e-17); 09X4X4 2.A.I.30.1 (4e-14); 055937 2.A.I.31.2 (3e-13) BC3251 1.2 MefA of Streptococcus progenes Macrolide efflux P95827 2.A.I.21.1 (1e-08); 07BKK4 2.A.I.21.2 (9e-07) 2.A.I.36 - The Unknown Major Facilitator-2 (UMP2) Family BC3350 i 90.4 YfkF of Bacillus subilis Possible drug exporter 034929 2.A.I.26.2 (2e-126); P21503 2.A.I.26.1 (7e-16); 056RY7 2.A.I.2.38 (1e-09) 2.A.I.31 - The Nickel Resistance (Nrc) Family BC4501 wrtstakin/surfactin exporter 034929 2.A.I.31.4 (0); 031561 2.A.I.31.3 (4e-38); 031137 2.A.I.21.3 (7e-16); 0750KK4 2.A.I.21.22 (3e-21) BC2501 97.6 Yfifs of Bacillus subilis Unknown 031561 2.A.I.31.3 (2e-17); 02WKA7 2.A.I.62.2 (7e-24); 07BKK4 2.A.I.21.22 (3e-21) BC2894 97.6 Yfifs of Bacillus subilis Unknown 031561 2.A.I.31.3 (2e-17); 02WKA7 2.A.I.62.2 (7e-23); 07BKK4 2.A.I.21.22 (3e-21) BC2894 97.6 Yfifs of Bacillus subilis Unknown	BC2411	83.4	MefE of Streptococcus pneumoniae	Macrolide efflux	Q7BKK4 2.A.1.21.22 (2e-23); P95827 2.A.1.21.1 (5e-21); C3WVU9 2.A.1.62.2 (3e-20)
BC0434* 98.2 TetV of Mycobacterium smegnatis Tetracycline resistance 031137 2.A.1.21.3 (4c-19); 031561 2.A.1.31.3 (2c-17); 09X4X4 2.A.1.30.1 (3c-13) BC325 MFS carrier of Thermoplasma Unknown 09HLP1 2.A.1.21.9 (3c-17); 09X4X4 2.A.1.30.1 (4c-14); 055937 2.A.1.31.2 (3c-13) BC325 I.2 MefA of Streptococcus progenes Macrolide efflux P95827 2.A.1.21.1 (1e-08); 07BKK4 2.A.1.20.2 (9e-07) 2.A.1.26 The Unknown Major Facilitator-2 (UMF2) Family Desible drug exporter 034929 2.A.1.26.2 (2c-126); P21503 2.A.1.26.1 (7e-16); 056RY7 2.A.1.2.3 (1e-09) 2.A.1.26 The Nickel Resistance (Nrc) Family Desible drug exporter 034929 2.A.1.26.2 (2c-126); P21503 2.A.1.21.4 (1e-08); 031137 2.A.1.21.3 (7e-15) BC1681* 97.6 Yfis of Bacillus subtilis Unknown 031561 2.A.1.31.3 (1e-27); C3WU9 2.A.1.62.2 (1e-24); 07BKK4 2.A.1.21.22 (2e-21) BC2890 97.0 NrsD of Symechocystis PCC6803 Ni2+ resistance protein Q55937 2.A.1.31.2 (2e-17); G3WU9 2.A.1.62.3 (7e-15); 07BKK4 2.A.1.21.22 (2e-14) BC2801 97.6 Yfis of Bacillus subtilis Unknown Q31561 2.A.1.31.3 (2e-17); G3WU9 2.A.1.62.3 (7e-15); 07BKK4 2.A.1.21.22 (2e-14) BC2802 97.6 Yfis of Bacillus subtilis Unknown Q31561 2.A.1.31.3 (2e-17);	BC2515		MFS porter of Stackebrandtia	Unknown	D3Q871 2.A.1.21.11 (4e-21); O31561 2.A.1.31.3 (1e-20); Q55937 2.A.1.31.2 (1e-20)
BC3225 MFS cariter of Thermoplasma acidophilum Unknown Q9HLP1 2.A.1.21.9 (3c-17); Q9X4X4 2.A.1.30.1 (4c-14); Q55937 2.A.1.31.2 (3c-13) BC3235 1.2 MefA of Streptococcus progenes Macrolide efflux P95827 2.A.1.21.1 (1e-08); Q7BKK4 2.A.1.22.1 (9c-07) 2.A.1.26 - The Unknown Major Facilitator-2 (UMF2) Family Possible drug exporter O34929 2.A.1.26.2 (2c-126); P21503 2.A.1.26.1 (7c-16); Q56RY7 2.A.1.23.8 (1e-09) 2.A.1.31 - The Nickel Resistance (Nre) Family Possible drug exporter O34929 2.A.1.31.4 (0); O31561 2.A.1.31.4 (e-38); O31137 2.A.1.21.2 (3c-15) BC1681* 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.2 (2c-20); O31137 2.A.1.21.2 (2c-12) BC2894* 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2c-16); Q56RY7 2.A.1.22.1 (2c-21) BC3101 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2c-16); Q56RY7 2.A.1.22.1 (2c-12) BC3205 IO Yfis of Bacillus subtilis Putative copper/multidrug efflux O35612 2.A.1.31.3 (2c-17); Q5WGH2 2.A.1.		63.9	nassauensis		
83.4 acidophilum BC32325 1.2 McfA of Streptococcus progenes Macrolide efflux P95827 2.A.1.21.1 (1e-08); Q7BKK4 2.A.1.21.22 (9e-07) CA.1.26 The Unknown Major Facilitator-2 (UMF2) Family O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) Z.A.1.31 The Nickel Resistance (Nre) Family BC2450 Kirst of Bacillus subilis Unknown O31561 2.A.1.31.4 (00; O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15) BC1681* 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.2 (2e-20); O31137 2.A.1.21.3 (7e-16); O7BKK4 2.A.1.21.22 (2e-21) BC2970 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-18); O3WU9 2.A.1.62.2 (1e-24); O7BKK4 2.A.1.21.22 (2e-21) BC2101 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-18); OSWGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (7e-16); CCP C1762	BC0434*	98.2	TetV of Mycobacterium smegmatis	Tetracycline resistance	O31137 2.A.1.21.3 (4e-19); O31561 2.A.1.31.3 (2e-17); Q9X4X4 2.A.1.30.1 (3e-13)
BC2325 1.2 McfA of Streptococcus progenes Macrolide efflux P95827 2.A.1.21.1 (1e-08); Q7BKK4 2.A.1.21.22 (9e-07) 2.A.1.26 - The Unknown Major Facilitator-2 (UMF2) Family 034929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) 2.A.1.31 - The Nickel Resistance (Nre) Family 034929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) 2.A.1.31 - The Nickel Resistance (Nre) Family Kurstakin/surfactin exporter 9.4 YKB of Bacillus subilis Unknown 031561 2.A.1.31.4 (0); 031561 2.A.1.31.3 (4e-38); 031137 2.A.1.21.3 (7e-15) 9.4 YKB of Bacillus subilis Unknown 031561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); 07BKK4 2.A.1.21.22 (2e-21) BC2894* 97.6 YfiS of Bacillus subilis Unknown 031561 2.A.1.31.3 (2e-18); 05WAS7 2.A.1.28 (6e-13); P5827 2.A.1.21.1 (1e-12) BC2804* 97.6 YfiS of Bacillus subilis Unknown 031561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.32 The Putative Aromatic Compound/Drug Exporter (ACDE) Family BC3072 100.0 YfmO of Bacillus subilis Putative copper/multidrug efflux 006473 2.A.1.32.3 (8e-83); Q54806 2.A.1.35.1 (1e-18); P0A017 2.A.1.210 (1e-18) BC3102 95.9 Fs of Escherichia coli	BC3225			Unknown	Q9HLP1 2.A.1.21.9 (3e-17); Q9X4X4 2.A.1.30.1 (4e-14); Q55937 2.A.1.31.2 (3e-13)
2.A.1.26 - The Unknown Major Facilitator-2 (UMF2) Family Possible drug exporter O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) BC310* 99.4 Yfkr of Bacillus subtilis Possible drug exporter O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) BC2450 KrsE of Bacillus cereus Kurstakin/surfactin exporter J8GQQ7 2.A.1.31.4 (0); O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15) BC1681* 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (2e-14) BC2894* 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-16); O358(12.A.1.31.3 (7e-15); O3WVU9 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (2e-12) BC2894* 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-17); O3WU9 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) SC2894* 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-17); O5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-14) BC2100 97.6 Yfis of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-83); Q54806 2.A.1.3.5 (1e-18); P0A017 2.A.1.2.10 (1e-18) SC3102 100.0 YfmO of Bacillus subtilis Putative		83.4	acidophilum		
BC3310* 99.4 YfkF of Bacillus subtilis Possible drug exporter O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09) 2.A.1.31 - The Nickel Resistance (Nre) Family Station (Nres of Bacillus cereus ortholog Kurstakin/surfactin ortholog IBGQQ7 2.A.1.31.4 (0); O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15) BC1681* 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); O7BKK4 2.A.1.21.22 (2e-12) BC2890 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-24); D7BKK4 2.A.1.21.22 (2e-14) BC2894* 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-17); O3WU9 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) BC2101 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-17); O3WH2 2.A.1.62.3 (7e-13); C3WU9 2.A.1.62.2 (2e-12) A.1.35 The Putative Aromatic Compound/Drug Exporter (ACDE) Family D06473 2.A.1.32.3 (8e-83); O54806 2.A.1.35.1 (8e-97); B3080 2.A.1.35.3 (5e-22) BC1762 95.9 Fst of Escherichia coli Fosmidomycin, trimethoprim and CCCP P52067 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) BC3162 54.4 Yga of Escherichia coli Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1	BC2325	1.2	MefA of Streptococcus pyogenes	Macrolide efflux	P95827 2.A.1.21.1 (1e-08); Q7BKK4 2.A.1.21.22 (9e-07)
2.A.1.31 - The Nickel Resistance (Nre) Family Kurstakin/surfactin exporter J8GQQ7 2.A.1.31.4 (0); O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15) BC1681* 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (2e-21) BC2894* 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.2 (2e-10); O31137 2.A.1.21.3 (7e-16); O7BKK4 2.A.1.21.22 (2e-21) BC2894* 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-18); O5WAS7 2.A.1.21.8 (6e-13); P5827 2.A.1.21.1 (1e-12) BC2610 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (2e-17); OSWGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.35 The Putative Aromatic Compound/Drug Exporter (ACDE) Family 006473 2.A.1.32.3 (8e-83); Q54806 2.A.1.35 (1e-18); P0A0J7 2.A.1.2.10 (1e-18) BC1762 95.9 Fsr of Escherichia coli Fosmidomycin, trimethoprim and CCCP P52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-32) CCCP 2.A.1.46 YgaY of Escherichia coli Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.45 The Unknown Major Facilitator-5 (UMF5) Family C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (
BC2450 KrsE of Bacillus cereits Kurstakin/surfactin exporter J8GQQ7 2.A.1.31.4 (0; O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15) 42.0 ortholog ortholog 0 031561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (2e-21) BC1681* 97.6 YfiS of Bacillus subtilis Unknown 031561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (2e-21) BC2970 97.0 NrsD of Synechocystis PCC6803 Ni2+ resistance protein Q55937 2.A.1.31.2 (2e-20); O31137 2.A.1.21.3 (7e-16); Q7BKK4 2.A.1.21.22 (2e-14) BC2610 97.6 YfiS of Bacillus subtilis Unknown 031561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.35 The Putative Aromatic Compound/Drug Exporter (ACDE) Family 006473 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.35 The Fosmidomycin Resistance (Fsr) Family 006473 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.1 (1e-18); P0A017 2.A.1.2.10 (1e-18) BC162 54.4 YgaY of Escherichia coli Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 The Unknown Major Facilitator-5 (UMF5) Family E BC0804 98.8 MFS porter of Bacillus cereus Putative qu				Possible drug exporter	O34929 2.A.1.26.2 (2e-126); P21503 2.A.1.26.1 (7e-16); Q56RY7 2.A.1.2.38 (1e-09)
42.0 ortholog Ortholog BC1681* 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (3e-21) BC2894* 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-20); O31137 2.A.1.21.3 (7e-16); Q7BKK4 2.A.1.21.22 (2e-14) BC2894* 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.32 - The Putative Aromatic Compound/Drug Exporter (ACDE) Family BC5372 100.0 YfinO of Bacillus subilis Putative copper/multidrug efflux O06473 2.A.1.32.3 (8e-83); Q54806 2.A.1.35.1 (1e-18); P0A017 2.A.1.2.10 (1e-18) 2.A.1.35 - The Fosmidomycin Resistance (Fsr) Family BC1762 95.9 Fsr of Escherichia coli Fosmidomycin, trimethoprim and CCCP 2.A.1.36 - The Acriflavin-sensitivity (YnfM) Family BC0804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family BC0804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A017 2.A.1.2.10 (3e-16) BC2283		The Nickel			
BC1681* 97.6 YfiS of Bacillus subtilis Unknown O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.2 (2e-21) BC2970 97.0 NrsD of Synechccystis PCC6803 Ni2+ resistance protein Q55937 2.A.1.31.2 (2e-20); Q31137 2.A.1.21.3 (7e-16); Q7BKK4 2.A.1.21.2 (2e-14) BC2804* 97.6 YfiS of Bacillus subtilis Unknown Q31561 2.A.1.31.3 (2e-18); Q5WAS7 2.A.1.21.8 (6e-13); P95827 2.A.1.21.1 (1e-12) 2.A.1.32 - The Putative Aromatic Compound/Drug Exporter (ACDE) Family Q031561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.35 - The Fosnidomycin Resistance (Fsr) Family Putative copper/multidrug efflux Q06473 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-22) 2.A.1.36 - The Acriflavin-sensitivity (YnfM) Family Fosmidomycin, trimethoprim and CCCP P52067 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) BC3804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (6e-24); P0A017 2.A.1.2.10 (3e-16) BC3814 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (6e-24); P0A017 2.A.1.2.10 (3e-16) BC3814 100.0 MFS porter of Bacillus cereus Putative quinolone resistance </th <td>BC2450</td> <td></td> <td>KrsE of Bacillus cereus</td> <td>Kurstakin/surfactin exporter</td> <td>J8GQQ7 2.A.1.31.4 (0); O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15)</td>	BC2450		KrsE of Bacillus cereus	Kurstakin/surfactin exporter	J8GQQ7 2.A.1.31.4 (0); O31561 2.A.1.31.3 (4e-38); O31137 2.A.1.21.3 (7e-15)
BC297097.0NrsD of Synechacystis PCC6803Ni2+ resistance proteinQ55937 2.A.1.31.2 (2e-20); O31137 2.A.1.21.3 (7e-16); Q7BKK4 2.A.1.21.2 (2e-14)BC2804*97.6Yfis of Bacillus subtilisUnknownO31561 2.A.1.31.3 (2e-18); Q5WAS7 2.A.1.21.8 (6e-13); P95827 2.A.1.21.1 (1e-12)BC261097.6Yfins of Bacillus subtilisUnknownO31561 2.A.1.31.3 (2e-18); Q5WAS7 2.A.1.21.8 (6e-13); P95827 2.A.1.21.1 (1e-12)BC2617297.6Yfins of Bacillus subtilisPutative copper/multidrug effluxO06473 2.A.1.32. (8e-83); Q54806 2.A.1.35. (1e-18); P0A0J7 2.A.1.2.10 (1e-18)BC372100.0YfmO of Bacillus subtilisPutative copper/multidrug effluxO06473 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F81C89 2.A.1.35.3 (5e-22)BC176295.9Fsr of Escherichia coliFosmidomycin, trimethoprim and CCCPP52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F81C89 2.A.1.35.3 (5e-22)BC316254.4YgaY of Escherichia coliUnknownP76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34)BC316254.4YgaY of Escherichia coliUnknownP76628 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16)BC283392.9MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19)BC3163100.0MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19)BC233492.9MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (2e-79)					
BC2894* 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-18); Q5WAS7 2.A.1.21.8 (6e-13); P95827 2.A.1.21.1 (1e-12) BC2610 97.6 YfiS of Bacillus subilis Unknown O31561 2.A.1.31.3 (2e-18); Q5WAS7 2.A.1.22.8 (6e-13); P95827 2.A.1.21.2 (2e-12) 2.A.1.32 - The Putative Aromatic Compound/Drug Exporter (ACDE) Family 0031561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12) 2.A.1.35 - The Formidomycin Resistance (Fsr) Family Putative copper/multidrug efflux 006473 2.A.1.32.3 (8e-83); Q54806 2.A.1.3.5 (1e-18); P0A0J7 2.A.1.2.10 (1e-18) 2.A.1.35 - The Formidomycin Resistance (Fsr) Family Fosmidomycin, trimethoprim and CCCP P52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F81C89 2.A.1.35.4 (5e-24) PA.1.66 - The Acriflavin-sensitivity (YnfN) Family Fosmidomycin, trimethoprim and CCCP P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC2833 92.9 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) BC3141 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e					O31561 2.A.1.31.3 (1e-27); C3WVU9 2.A.1.62.2 (1e-24); Q7BKK4 2.A.1.21.22 (3e-21)
BC261097.6YfiS of Bacillus subtilisUnknownO31561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12)2.A.1.32 - The Futative Aromatic Compound/Drug Exporter (ACDE) FamilyD00.473 2.A.1.32.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12)BC37210.0YfmO of Bacillus subtilisPutative copper/multidrug effluxO06473 2.A.1.32.3 (8e-83); Q54806 2.A.1.35. (1e-18); P0A0J7 2.A.1.2.10 (1e-18)2.A.1.35 - The Formitomycin Resistance (Fsr) FamilyFsr of Escherichia coliFosmidomycin, trimethoprim and CCPP52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-22)2.A.1.36 - The Acriflavin-sensitivity (YnfM) FamilyEC208Value of Escherichia coliUnknownP76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34)2.A.1.46 - The UnknownMajor Facilitator-5 (UMF5) FamilyPutative quinolone resistanceC2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16)BC2080498.8MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (4e-19)BC314100.0MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18)BC316758.8Phile of Fusobacterium sp. 7_1Putative Macrolide efflux, possiblyC3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21)BC3197VP-MEP of Fusobacterium sp. 7_1Putative Macrolide efflux, possiblyC3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11) <th></th> <th></th> <th>· · ·</th> <th>Ni2+ resistance protein</th> <th></th>			· · ·	Ni2+ resistance protein	
2.A.1.32 - The Putative Aromatic Compound/Drug Exporter (ACDE) Family 0.0 YfmO of Bacillus subtilis Putative copper/multidrug efflux 006473 2.A.1.32.3 (8e-83); Q54806 2.A.1.3.5 (1e-18); P0A0J7 2.A.1.2.10 (1e-18) 2.A.1.35 - The Fosmidomycin Resistance (Fsr) Family 006473 2.A.1.32.1 (8e-83); Q54806 2.A.1.3.5 (1e-78); F8IC89 2.A.1.2.10 (1e-18) BC1762 95.9 Fsr of Escherichia coli Fosmidomycin, trimethoprim and CCCP 2.A.1.36 - The Acriflavin-sensitivity (YnfM) Family P52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-22) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family Ptative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC20804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) 2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family Extreme C2UR80 2.A.1.46.5 (2e-24); P05827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.21 (2e-21) 85.8 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide eff					
BC5372 100.0 YfmO of Bacillus subtilis Putative copper/multidrug efflux 006473 2.A.1.32.3 (8e-83); Q54806 2.A.1.3.5 (1e-18); P0A0J7 2.A.1.2.10 (1e-18) 2.A.1.35 - The Fosmidomycin Resistance (Fsr) Family BC1762 95.9 Fsr of Escherichia coli Fosmidomycin, trimethoprim and CCP P52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-22) 2.A.1.36 - The Acriflavin-sensitivity (YnfM) Family BC3162 54.4 YgaY of Escherichia coli Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family BC0804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC283 92.9 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) 2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family E E E E BC230* 94.1 UMF11 of Staphylococccus aureus Unknown A8YZ14 2.A.		2110			O31561 2.A.1.31.3 (2e-17); Q5WGH2 2.A.1.62.3 (7e-15); C3WVU9 2.A.1.62.2 (2e-12)
2.A.1.35 - The Fosmidomycin Resistance (Fsr) Family Image: Constraint of the constraint of t		The Putativ			
BC1762 95.9 Fsr of <i>Escherichia coli</i> Fosmidomycin, trimethoprim and CCCP P52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-22) 2.A.1.36 - The Acriflavin-sensitivity (YnfM) Family BC3162 54.4 YgaY of <i>Escherichia coli</i> Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family BC0804 98.8 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC2828 92.9 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC314 100.0 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) 2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family Family C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) 85.8 P-MEP of <i>Fusobacterium</i> sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.2 (2e-21) 85.8 94.1 UMF11 of <i>Staphylococcus aureus</i> Unknown A8YZ14 2.A.1.62.1 (1e-				Putative copper/multidrug efflux	O06473 2.A.1.32.3 (8e-83); Q54806 2.A.1.3.5 (1e-18); P0A0J7 2.A.1.2.10 (1e-18)
CCCPCCCP2.A.1.36 - The Acriflavin-sensitivity (YnfM) FamilyBC316254.4YgaY of Escherichia coliUnknownP76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34)2.A.1.46 - The UnknownMajor Facilitator-5 (UMF5) FamilyBC080498.8MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16)BC228392.9MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19)BC3314100.0MFS porter of Bacillus cereusPutative quinolone resistanceC2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18)2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) FamilyEBC2673P-MEP of Fusobacterium sp. 7_1Putative Macrolide efflux, possibly amino acid transportC3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) amino acid transportBC230*94.1UMF11 of Staphylococcus aureusUnknownA8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07)BC3197P-MEP of Fusobacterium sp. 7_1Putative Macrolide efflux, possibly attive Macrolide efflux, possibly attive Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)	2.A.1.35 - 1	The Fosmid	omycin Resistance (Fsr) Family		
2.A.1.36 - The Acriflavin-sensitivity (YnfM) Family BC3162 54.4 YgaY of Escherichia coli Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family BC0804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC283 92.9 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) BC2673 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.2 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)	BC1762	95.9	Fsr of Escherichia coli	Fosmidomycin, trimethoprim and	P52067 2.A.1.35.1 (3e-97); Q56877 2.A.1.35.2 (1e-78); F8IC89 2.A.1.35.3 (5e-22)
BC3162 54.4 YgaY of <i>Escherichia coli</i> Unknown P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34) 2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family Pace Pace C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC0804 98.8 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC2283 92.9 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (1e-21); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) BC3673 P-MEP of <i>Fusobacterium</i> sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) amino acid transport BC2230* 94.1 UMF11 of <i>Staphylococcus aureus</i> Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of <i>Fusobacterium</i> sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)				CCCP	
2.A.1.46 - The Unknown Major Facilitator-5 (UMF5) Family BC0804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC2283 92.9 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) 2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) amino acid transport BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					
BC0804 98.8 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (0); B8GFY3 2.A.1.46.4 (2e-26); P0A0J7 2.A.1.2.10 (3e-16) BC2283 92.9 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) 2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.2 (2e-21) BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					P76628 2.A.1.36.3 (1e-72); A8GHT9 2.A.1.36.2 (2e-54); Q9ADP8 2.A.1.36.4 (5e-34)
BC2283 92.9 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (4e-104); B8GFY3 2.A.1.46.4 (6e-24); P0A0J7 2.A.1.2.10 (4e-19) BC3314 100.0 MFS porter of Bacillus cereus Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family Family C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2673 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					
BC3314 100.0 MFS porter of <i>Bacillus cereus</i> Putative quinolone resistance C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18) 2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family Family C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2673 P-MEP of <i>Fusobacterium</i> sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2230* 94.1 UMF11 of <i>Staphylococcus aureus</i> Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of <i>Fusobacterium</i> sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					
2.A.1.62 - The Unidentified Major Facilitator-11 (UMF11) Family BC2673 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly amino acid transport BC2673 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					
BC2673 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly amino acid transport C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21) BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					C2UR80 2.A.1.46.5 (2e-79); B8GFY3 2.A.1.46.4 (1e-21); P37621 2.A.1.46.7 (1e-18)
85.8 amino acid transport BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)		The Uniden			
BC2230* 94.1 UMF11 of Staphylococcus aureus Unknown A8YZ14 2.A.1.62.1 (1e-18); P95827 2.A.1.21.1 (9e-08); P64783 2.A.1.21.12 (3e-07) BC3197 P-MEP of Fusobacterium sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)	BC2673		P-MEP of Fusobacterium sp. 7_1		C3WVU9 2.A.1.62.2 (2e-24); P95827 2.A.1.21.1 (2e-23); Q7BKK4 2.A.1.21.22 (2e-21)
BC3197 P-MEP of <i>Fusobacterium</i> sp. 7_1 Putative Macrolide efflux, possibly C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)					
		94.1			
12.4 amino acid transport	BC3197		P-MEP of Fusobacterium sp. 7_1		C3WVU9 2.A.1.62.2 (7e-15); D3Q871 2.A.1.21.11 (6e-11); Q55937 2.A.1.31.2 (1e-11)
		12.4		amino acid transport	

a. Numbers show the percent conservation of the protein in the predicted proteomes of 169 *B. cereus* group isolates according to comparative BLASTP
 searches (see Fig 1).

b. Uniprot accession numbers, TCDB accession numbers (boldface font) and e-values (in parentheses) for the top three blastp hits (e-value < 1e-5)

- c. Blast hits for each family are in descending order of e-value for top hit* genes marked with an asterisk were targeted by qRT-PCR analyses, see text for details.

Some B. cereus group MFS efflux pumps are likely to mediate the efflux of 288 endogenously produced secondary metabolites. For example, BC2310 is located in a gene 289 290 cluster encoding for biosynthesis of bacillibactin [34], and is likely to mediate the efflux of this siderophore or a biosynthetic intermediate. BC2450 encodes an efflux pump that may 291 transport a cyclic lipopeptide. Of the transporters listed in the TCDB, the BC2450 pump is 292 most similar to the nickel resistance (Nre) family pump KrsE encoded by B. cereus VD014 293 (99% identical) (Table 2). The KrsE pump is encoded by the first gene in a large (~30 kb) six-294 295 gene cluster that includes several non-ribosomal peptide synthase genes involved in the biosynthesis of a cyclic lipopeptide, kurstakin. The cluster is also found in ATCC 14579 [35], 296 but is not active in this strain, possibly due to a transposon insertion in this strain in the 297 298 quorum sensing regulator gene, *nprR*, which regulates production of kurstakin [36]. The role 299 of KrsE in the efflux of kurstakin lipopeptides is yet to be demonstrated in B. cereus group strains, but a recent study demonstrated that an orthologous pump is involved in the efflux of 300 301 a surfactin in *B. subtilis* [37]. Surfactin has been shown by a number of studies to be essential for formation of mature biofilms by *B. subtilis* [38,39]. 302

Several putative *B. cereus* MFS efflux pumps were very similar to characterised multidrug efflux pumps encoded by *B. subtilis* (e-value=0; Table 2). These included the DHA1 family pump BC0855 (74% identity, 86% similarity to Blt), and the DHA2 family pumps BC4000 (62% identity, 76% similarity to Bmr3), BC2880 (60% identity, 76% similarity to Bmr3) and BC0658 (75% identity, 88% similarity to MdrP) (Table 2). Therefore, these *B. cereus* pumps may also mediate multidrug resistance.

Blt of *B. subtilis* was first recognised as being a multidrug efflux pump able to confer resistance to a range of substrates when overexpressed. Deletion of this gene from *B. subtilis* did not cause a decrease in antimicrobial resistance [40], possibly because *blt* has a low basal expression level and is not induced by antimicrobial substrates [16]. In addition to

antimicrobials, the Blt multidrug efflux pump in *B. subtilis* is thought to have a physiological 313 role in polyamine transport since the *blt* gene is encoded adjacent to a polyamine 314 acetyltransferase gene and appears to promote the efflux of spermidine [41]. In contrast, the 315 BC0855 gene is not encoded adjacent to a polyamine acetyltransferase gene, but is in a small 316 cluster that also includes the SMR family transport protein genes BC0852 and BC0853 (see 317 below), and a TetR family regulator gene BC0854. A partially palindromic sequence motif is 318 conserved upstream of the BC0855 pump, the BC0854 regulator and the BC0852/BC0853 319 SMR pump genes with consensus: 5'-AAAaTGAxTGAtAGTCAtTCA-3' (capital letters are 320 in all three upstream regions, lower case in two and x is different in all). This may be a 321 322 binding site for a regulatory protein, possibly that encoded by BC0854. Indeed, it was seen that in *B. anthracis* mutations in the orthologous regulator gene and/or its promoter region 323 appeared to be responsible for derepression of all genes in the orthologous cluster. The 324 325 increased expression of the transporter genes may have been responsible for ciprofloxacin resistance in *B. anthracis* [42]. A similar sequence (5'-AAAATAATTGACAGTCATTCA-3') 326 is found approximately 50 nt upstream of a putative biotin biosynthetic gene cluster (BC4120-327 BC4114) in the B. cereus ATCC 14579 genome, however, the relevance of this is unknown. 328

329 ATP-binding cassette superfamily efflux pumps encoded in B.

330 *cereus* ATCC 14579

331 Similar to the MFS the ABC superfamily of transport proteins is large and ancient, and 332 ubiquitous to all classes of living organisms. In bacteria ABC superfamily pumps promote a 333 range of both efflux and uptake transport reactions with substrates that include metabolites, 334 vitamins, amino acids, lipids, peptides, ions and drugs. ABC superfamily pumps have been 335 associated with drug resistance in bacteria and the cells of higher organisms, such as human 336 cancer cells. The representative *B. cereus* group isolates examined in this work, *B. anthracis* Ames, *B. cereus* ATCC 14579 and *B. thuringensis* konkukian 97-27, each encoded between
28 and 35 ABC superfamily efflux pumps.

339 Comparisons of the ABC superfamily pumps identified in *B. cereus* ATCC 14579 with those in the TCDB using BLASTP identified several putative efflux systems that were closely 340 341 related to previously characterised drug efflux pumps (e-value=0; Table 3). These included two pumps that were similar to the YheI/YheH heterodimeric ABC superfamily multidrug 342 efflux pump in B. subtilis, renamed as BmrC/BmrD [43,44]; BC0870/BC0871 (65%/64% 343 344 identity and 82%/80% similarity to the BmrC/BmrD), BC3679/BC3678 (48%/45% identity, 66%/67% similarity to BmrC/BmrD). In B. subtilis expression of BmrC/BmrD is responsive 345 to ribosome-targeting antibiotics, and is controlled by a transcriptional attenuation mechanism 346 347 that involves stem-loop structures upstream of *bmrC*, as well as a leader peptide BmrB which 348 is encoded on the same transcript as bmrC/bmrD [45]. BC0870/BC0871 is most closely related to bmrC/bmrD in B. cereus ATCC 14579. BC0870 expression is also highly 349 350 transcriptionally responsive to several ribosome targeting antibiotics (see below). The region upstream of BC0870 in B. cereus ATCC 14579 also contains sequences that could form stable 351 stem-loop structures that may facilitate a similar mode of regulation in this strain. However, 352 no clear homolog of BrmB is encoded in this region, highlighting a need for future 353 354 experiments to investigate the regulation of BC0870/BC0871 in B. cereus group isolates.

Locus tag	Conse rvatio n ^a	Best match name	Function(s) of best match	Locali sation	Top blastp hit(s) ^c
3.A.1.105:	The Drug	g Exporter-1 (DrugE1) Family			
BC1734	100.0	ABC2 of Bacillus cereus	Unknown	С	J8ABC0 3.A.1.105.9 (2e-101); Q9A0K0 3.A.1.105.7 (7e-93); Q7UE58 3.A.1.105.8 (1e-67)
BC1735	99.4	SagGHI (Firmicutes)	May export streptolysin S	М	Q9A0J9 3.A.1.105.7 (1e-37); J7ZHK9 3.A.1.105.9 (1e-13); J8A8S6 3.A.1.105.9 (1e-8)
BC1736	97.6	SagGHI (Firmicutes)	May export streptolysin S	М	Q9A0J8 3.A.1.105.7 (1e-51); J7ZHK9 3.A.1.105.9 (3e-34); J8A8S6 3.A.1.105.9 (1e-15)
BC2478	94.1	ABC2 of <i>Bacillus cereus</i> ABC-2 of <i>Dehalococcoides</i>	Unknown	C	J8ABC0 3.A.1.105.9 (4e-63); Q3Z8A8 3.A.1.105.6 (6e-62); Q4VWC9 3.A.1.105.4 (3e-56)
BC2479	93.5	ethenogenes	Unknown	М	Q3Z8A7 3.A.1.105.6 (3e-54); P0AFP9 3.A.1.105.15 (5e-15); Q4VWC7 3.A.1.105.4 (6e-13)
BC3435	98.8	OleC5ofStreptomycesantibioticusOleC4ofStreptomyces	Drug resistance	М	Q53717 3.A.1.105.2 (3e-31); P32011 3.A.1.105.1 (2e-28); Q9F2Y7 3.A.1.105.13 (3e-22)
BC3436	98.8	antibioticus	Drug resistance	С	Q53716 3.A.1.105.2 (1e-75); Q9F2Y8 3.A.1.105.13 (3e-74); P32010 3.A.1.105.1 (6e-71)
3.A.1.106:	The Lipi	d Exporter (LipidE) Family			
		Sav1866 of Staphylococcus			
BC0509*	100.0	aureus	Multidrug resistance	MC	Q2G2M9 3.A.1.106.2 (0); Q8G7R7 3.A.1.106.3 (1e-120); Q9WYC4 3.A.1.135.5 (4e-120)
BC0870*	100.0	YheI of Bacillus subtilis	Multidrug resistance	MC	O07550 3.A.1.106.8 (0); P77265 3. A.1.106.13 (1e-162); A7VN01 3.A.1.106.5 (2e-154)
BC0871	68.6	YheH of Bacillus subtilis	Multidrug resistance	MC	O07549 3.A.1.106.8 (0); P0AAG5 3.A.1.106.13 (1e-123); A7VN02 3.A.1.106.5 (8e-113)
BC3678	98.8	YheH of Bacillus subtilis	Multidrug resistance	MC	007549 3.A.1.106.8 (9e-164); Q9WYC4 3.A.1.135.5 (1e-142); A7VN02 3.A.1.106.5 (5e-132)
BC3679	99.4	YheI of Bacillus subtilis	Multidrug resistance	MC	O07550 3.A.1.106.8 (0); P77265 3.A.1.106.13 (0); A7VN01 3.A.1.106.5 (0)
		Sav1866 of Staphylococcus			Q2G2M9 3.A.1.106.2 (8e-127); Q8G7R7 3.A.1.106.3 (5e-112); Q9WYC4 3.A.1.135.5 (4
BC5182*	97.0	aureus	Multidrug resistance	MC	111)
	The Drug	g Exporter-2 (DrugE2) Family			
BC1955	94.7	BmrA of Bacillus subtilis	Multidrug resistance	MC	O06967 3.A.1.117.3 (0); P97046 3.A.1.117.1 (5e-162); O32748 3.A.1.117.2 (9e-162)
3.A.1.122:	The Mac	rolide Exporter (MacB) Family			
		ABC transporter of			
BC0764	77.5	Methanocaldococcus jannaschii	Unknown	С	Q58206 3.A.1.122.14 (3e-67); O31711 3.A.1.122.2 (1e-64); Q8RKC1 3.A.1.122.3 (8e-64)
BC0814	100.0	YknZ of Bacillus subtilis	Antimicrobial peptide	М	O31712 3.A.1.122.2 (2e-73); A0ZUB1 3.A.1.122.12 (2e-48); P75831 3.A.1.122.1 (6e-48)
BC0815	99.4	YknY of Bacillus subtilis	Antimicrobial peptide	С	O31711 3.A.1.122.2 (5e-107); Q58206 3.A.1.122.14 (8e-76); Q8RKC1 3.A.1.122.3 (1e-73)
BC3222	98.2	HrtA of <i>Staphylococcus aureus</i> HrtB of <i>Corynebacterium</i>	Probable Heme exporter	С	Q7A3X3 3.A.1.122.4 (8e-63); Q58206 3.A.1.122.14 (6e-59); A8TDW7 3.A.1.122.7 (9e-59)
BC3223	99.4	diphtheriae	Hemin resistance	М	H2GZC4 3.A.1.122.11 (4e-28); Q8TM31 3.A.1.122.6 (2e-7)
BC5253	99.4	YknZ of Bacillus subtilis	Antimicrobial peptide	М	O31712 3.A.1.122.2 (3e-109); A0ZUB1 3.A.1.122.12 (6e-59); P75831 3.A.1.122.1 (9e-46)
BC5254	98.8	YknY of Bacillus subtilis	Antimicrobial peptide	С	O31711 3.A.1.122.2 (4e-99); Q58206 3.A.1.122.14 (7e-85); A8TDW7 3.A.1.122.7 (2e-75)
3.A.1.124:	The 3-co	mponent Peptide-5 Exporter (Pep5	E) Family		
BC4221	94.1	SboF of Streptococcus salivarius	Salivaricin exporter	С	Q09II0 3.A.1.124.5 (1e-40); Q75V15 3.A.1.124.3 (5e-38); Q45404 3.A.1.124.2 (1e-36)
3.A.1.126:	The β-Ex	otoxin I Exporter (βΕΤΕ) Family	•		
BC3590	97.6	BerB of Bacillus thuringiensis	Exporter of β-exotoxin I	М	Q8RME0 3.A.1.126.1 (2e-175)

355Table 3. Putative B. cereus ATCC 14579 ABC efflux pumps

BC3591	99.4	BerA of Bacillus thuringiensis	Exporter of β-exotoxin I	С	Q8RME1 3.A.1.126.1 (0); H8I779 3.A.1.132.8 (3e-47); P42332 3.A.1.131.1 (8e-47)
3.A.1.132:	The Glid	ing Motility ABC Transporter (Gld) Family		
		ABC-2 of <i>Streptococcus</i>			Q99ZC8 3.A.1.132.6 (1e-31); Q8RME1 3.A.1.126.1 (1e-29); O30489 3.A.1.132.1 (1e-28)
BC2902	83.4	pyogenes	Unknown	С	
	The Pept	tide-7 Exporter (Pep7E) Family			
BC2543	98.2	YxdL of Bacillus subtilis	Peptide/multidrug	С	P42423 3.A.1.134.6 (8e-120); O06980 3.A.1.134.5 (6e-115); Q8Y5F0 3.A.1.134.12 (5e-97)
BC2544	68.0	YxdM of Bacillus subtilis	Peptide/multidrug	М	P42424 3.A.1.134.6 (4e-116); O06981 3.A.1.134.5 (9e-72); Q8Y5E9 3.A.1.134.12 (7e-50)
BC4823	21.3	AnrB of Listeria monocytogenes	Multidrug resistance	М	Q8Y5E9 3.A.1.134.12 (7e-141); Q8VUH1 3.A.1.134.2 (2e-61); O34741 3.A.1.134.3 (5e-61)
BC4824	0.0^{d}	AnrA of Listeria monocytogenes	Multidrug resistance	С	Q8Y5F0 3.A.1.134.12 (4e-65); O06980 3.A.1.134.5 (2e-52); O34697 3.A.1.134.3 (2e-50)
BC4830	99.4	AnrB of Listeria monocytogenes	Multidrug resistance	М	Q8Y5E9 3.A.1.134.12 (2e-150); O06981 3.A.1.134.5 (3e-64); O34741 3.A.1.134.3 (8e-64)
BC4831	99.4	AnrA of Listeria monocytogenes	Multidrug resistance	С	Q8Y5F0 3.A.1.134.12 (5e-125); O34697 3.A.1.134.3 (1e-98); O06980 3.A.1.134.5 (1e-95)
3.A.1.135:	The Dru	g Exporter-4 (DrugE4) Family			
BC2371	98.2	TM287 of Thermatoga maritima	Unknown	MC	Q9WYC3 3.A.1.135.5 (1e-175); B8ZPJ9 3.A.1.135.4 (8e-137); G9CHY8 3.A.1.135.3 (4e-136)
BC2372	98.8	TM288 of Thermatoga maritima	Unknown	MC	Q9WYC4 3.A.1.135.5 (0); B8ZPD1 3.A.1.135.4 (1e-145); Q8G7R7 3.A.1.106.3 (3e-145)
3.A.1.141:	The Ethy	vl Viologen Exporter (EVE) Family	(DUF990 Family)		
		EvrA of Synechocystis sp.	× × ¢		
BC0513	100.0	PCC6803	Ethyl viologen export	С	P73329 3.A.1.141.1 (2e-85); Q8R6Q4 3.A.1.141.2 (1e-65); P46903 3.A.1.115.1 (5e-48)
		AbcB of Thermoanaerobacter			
BC0514	98.2	tengcongensis	Unknown	М	Q8R6Q5 3.A.1.141.2 (6e-21)
		EvrC of Synechocystis sp.			
BC0515	100.0	PCC6803	Ethyl viologen export	М	P74757 3.A.1.141.1 (2e-14); Q8R6Q6 3.A.1.141.2 (9e-6);
3.A.1.147:					
		Exporter of Natranaerobius			
BC3328	96.4	thermophilus	Unknown	М	B2A6N2 3.A.1.147.5 (2e-9); J7IPE5 3.A.1.147.10 (4e-9); C9XJW9 3.A.1.147.6 (9e-8)
BC3329	100.0	Exporter of Clostridium difficile	Unknown	С	C9XJX0 3.A.1.147.6 (3e-88); C1A6K8 3.A.1.147.1 (3e-75); B8ZKM9 3.A.1.147.8 (1e-74)
No clear fa	mily				
		ABC-2 of Streptococcus			
BC1357	100.0	pyogenes	Unknown	С	Q99ZC8 3.A.1.132.6 (7e-68); P46903 3.A.1.115.1 (5e-30); Q2SDB1 3.A.1.132.4 (5e-29)
BC1358	20.7	ŇĂ	NA		no significant hits
BC1359*	100.0	SboF of Streptococcus salivarius	Salivaricin exporter	С	Q09II0 3.A.1.124.5 (4e-65); P42332 3.A.1.131.1 (1e-62); Q75V15 3.A.1.124.3 (2e-60)
BC1360	100.0	NA	NA		no significant hits
BC2719	7.7	SboF of Streptococcus salivarius	Salivaricin exporter	С	Q09II0 3.A.1.124.5 (3e-56); Q75V15 3.A.1.124.3 (3e-55); P42332 3.A.1.131.1 (1e-50)
BC2720	7.7	_	_		no significant hits
BC3665	70.4	NA	NA		no significant hits
BC3666	66.9	SboF of Streptococcus salivarius	Salivaricin exporter	С	Q09II0 3.A.1.124.5 (1e-69); A6MER5 3.A.1.124.4 (2e-64); Q75V15 3.A.1.124.3 (2e-62)
BC4533	100.0	NA	NA		no significant hits
BC4535	96.4	NA	NA		no significant hits
BC4537	100.0	BcrA of Bacillus licheniformis	bacitracin resistance	С	P42332 3.A.1.131.1 (3e-94); Q09II0 3.A.1.124.5 (1e-68); Q75V15 3.A.1.124.3 (2e-65)
BC5284	97.0	PltJ of Pseudomonas sp. M18	Polyketide efflux	М	Q4VWC8 3.A.1.105.4 (3e-6)
		ABC2 #2 of <i>Methanocella</i>	-		
BC5285*	100.0	arvoryzae	Unknown	С	Q0W8T7 3.A.1.144.2 (8e-56); J8ABC0 3.A.1.105.9 (7e-53); Q0W8T4 3.A.1.144.1 (3e-52)
BC5399	100.0	NatB of Rhodopirellula baltica	Na extrusion (putative)	М	Q7UQ82 3.A.1.115.2 (1e-7); Q7NL24 3.A.1.132.10 (5e-6);

	BC5400	100.0	BcrA of Bacillus licheniformis	Bacitracin resistance	С	P42332 3.A.1.131.1 (7e-80); Q09II0 3.A.1.124.5 (2e-69); H8I779 3.A.1.132.8 (4e-67)
ſ	BC5431	31.4	NA	NA		no significant hits
	BC5433*	100.0	CmpA of Clostridium hathewayi	Drug transport	М	Q83XH1 3.A.1.121.4 (1e-54); P43672 3.A.1.120.6 (3e-54); Q60248 3.A.1.120.4 (2e-47)

a. Numbers show the percent conservation of the protein in the predicted proteomes of 169 *B. cereus* group isolates according to comparative BLASTP searches (see Fig 1).

b. Localization, M: transmembrane domain, C: cytoplasmic ATP-binding domain, MC: fused membrane and cytoplasmic domains.

359 c. Uniprot accession numbers, TCDB accession numbers (boldface font) and e-values (in parentheses) for the top three blastp hits (e-value < 1e-5).

360 *d*. BC4824 is annotated as a pseudogene, and is thus not associated with a protein coding sequence.

361 * genes marked with an asterisk were targeted by qRT-PCR analyses, see text for details.

Three other ABC efflux systems identified in *B. cereus* ATCC 14579 were also closely related to previously characterised drug efflux pumps listed in the TCDB and may function in drug efflux. These include, BC1955 (63% identity, 78% similarity to BmrA of *Bacillus subtilis*), BC0509 (59% identity, 78% similarity to Sav1866 of *Staphylococcus aureus*), and BC2371/BC2372 (45%/46% identity, 66%/66% similarity to TM287/TM288 of *Thermatoga maritima*).

The transporter encoded by BC3590/BC3591 is orthologous to the BerA/BerB 368 transport system of *B. thuringensis* (95%/99% Identity, 97%/99% similarity), which has been 369 linked to β -exotoxin production/efflux [46]. The organisation of genes adjacent to 370 BC3590/BC3591 is identical in *B. cereus* ATCC 14579 and the β-exotoxin producing strain 371 B. thuringiensis 407-1 [47]. Therefore, the regulation of BC3590/BC3591 in B. cereus ATCC 372 373 14579 may be similar to berA/berB in B. thuringiensis. However, B. cereus ATCC 14579 does not produce β-exotoxin, so the function of the pump encoded by BC3590/BC3591 is 374 unknown. Genes encoding BerA/BerB orthologs are conserved in 97.6-99.4% of B. cereus 375 376 group isolates (Fig 1B; Table 3), therefore this ABC pump may have a core physiological function, potentially playing a fortuitous role in β -exotoxin transport in strains that produce 377 this toxin. 378

379 Resistance/nodulation/division superfamily efflux pumps encoded

380 in *l*

in *B. cereus* ATCC 14579

Transport proteins classified within the RND superfamily of efflux pumps facilitate the efflux of diverse substrates including antimicrobials, metals and lipids. Specialised RND pumps within the SecDF family form accessory components of the Sec-translocase and thus participate in protein secretion. In Gram-negative bacteria most RND pumps that mediate small molecule transport are thought to form complexes with membrane fusion proteins and

outer-membrane proteins that allow substrates to be captured within the periplasm or outer 386 387 leaflet of the inner-membrane and transported across the outer-membrane. For example, the periplasmic head domain in the AcrB RND pump from E. coli docks with the TolC outer-388 membrane protein and the AcrA membrane fusion protein to move substrates across the 389 outer-membrane [48]. It remains to be demonstrated whether RND pumps are able to capture 390 substrates from within the bacterial cytoplasm. Since Gram-positive bacteria do not have an 391 outer-membrane, the substrates and molecular transport mechanisms of Gram-positive RND 392 efflux pumps, such as those encoded by stains within the *B. cereus* group, are of particular 393 interest. 394

The genome of B. cereus ATCC 14579 encodes four RND superfamily transporters, 395 396 BC0714, BC1291, BC4405 and BC5435. One of these proteins, BC4405, has been studied 397 previously by members of our team and shown to encode the SecDF component of the Sectranslocase [49]. BLASTP and phylogenetic analyses conducted here confirmed the 398 399 relationship of BC4405 and other SecDF RND proteins within the SecDF family (TCDB 2.A.6.4) (Table 4). The functions of the remaining three RND proteins in *B. cereus* ATCC 400 14579 are unknown, but may involve drug efflux (Table 1). Each of these proteins is highly 401 conserved in at least 96 % of sequenced representatives in the *B. cereus* group (Table 4; Fig. 402 403 1), suggesting an important core function (Table 4).

405 Table 4. Putative *B. cereus* ATCC 14579 RND efflux pumps

Locus tag	Conser	Best match name	Function(s) of best match	Top blastp hit(s) ^b
	vation ^a			
BC_0714	96.4	YerP of Bacillus subtilis	Surfactin export	D4G632 2.A.6.3.9 (0); Q8CX78 2.A.6.3.6 (6e-128); B4WH09 2.A.6.3.5 (4e-116)
		MmpL3 of Mycobacterium	Trehalose monomycolate export	
BC_1291	100.0	tuberculosis		O53657 2.A.6.5.6 (2e-77); P65374 2.A.6.5.5 (3e-35); Q53902 2.A.6.5.1 (3e-34)
BC_4405	100.0	SecDF of Bacillus subtilis	Protein translocation	O32047 2.A.6.4.2 (0); Q5SKE6 2.A.6.4.3 (3e-102); P0AG90 2.A.6.4.1 (2e-43)
BC_5435	99.4	YerP of Bacillus subtilis	Surfactin export	D4G632 2.A.6.3.9 (0); Q8CX78 2.A.6.3.6 (7e-149); Q1DEX6 2.A.6.3.4 (2e-135)

406 *a.* Numbers show the percent conservation of the protein in the predicted proteomes of 169 *B. cereus* group isolates according to comparative BLASTP 407 searches (see Fig 1).

408 b. Uniprot accession numbers, TCDB accession numbers (boldface font) and e-values (in parentheses) for the top three blastp hits (e-value < 1e-5).

BLASTP and phylogenetic analyses showed that the BC0714 and BC5435 pumps 409 should be classified as members of the putative nodulation factor exporter (NFE) family 410 411 (TCDB 2.A.6.3) and are most closely related to YerP from B. subtilis (Table 4). Functional analyses of YerP recently demonstrated that overexpression of this pump in its native host 412 resulted in increased secretion of endogenously produced surfactin into the supernatant [37]. 413 YerP is also known to be involved in surfactin resistance in strains that do not produce an 414 endogenous surfactin and can mediate resistance to acriflavine and ethidium [50]. 415 416 Amphiphilic substrates such as surfactin, acriflavine or ethidium could be present in the outerleaflet of the cytoplasmic membrane in *Bacillus* species and be stripped from this location by 417 418 an RND pump, then expelled into the environment. Similar to YerP, BC0714 and BC5435 419 may recognise an endogenous substrate. A noteworthy feature of the BC5435 sequence was 420 the presence of an extended periplasmic loop in the region corresponding to the TolC docking 421 domain of the structurally characterised AcrB pump (S1 Fig). An extended loop is also 422 present in the *B. subtilis* YerP protein, but not in any of the other RND proteins currently listed in TCDB. The loop in BC5435 is glutamine, serine and alanine-rich which may be 423 important for function, possibly playing a role in substrate release given the putative location 424 of the loops near the substrate exit site. 425

The fourth RND pump encoded by *B. cereus* ATCC 14579, BC1291, fell within the (Gram-positive bacterial putative) hydrophobe/amphiphile efflux-2 (HAE2) family (TCDB 2.A.6.5) clade (Table 4). Most of the characterised pumps in this family transport lipids or cell wall components. With respect to proteins listed in the TCDB, BC1291 is most related to MmpL3 and MmpL11 from *Mycobacterium tuberculosis*, which transport mycobacterial specific cell wall components (Table 4). The YdfJ system encoded in *B. subtilis* is also a member of the HAE2 family. A deletion mutant of this pump did not show increased 433 susceptibility to a panel of more than 31 antimicrobials [51]. Therefore, these pumps may not434 have any cross-specificity for drugs.

435 Small multidrug resistance family efflux pumps encoded in *B*. 436 *cereus* ATCC 14579

The SMR family is classified within the drug/metabolite superfamily, which also 437 includes families of pumps that mediate the export or uptake of a range of sugars, amino acids 438 439 and other metabolites. Transporters classified within the SMR family are the smallest known efflux pumps that have been characterised to date. A complete SMR transport system consists 440 of two polypeptides, each approximately 110 amino acids in length, and can be homo- or 441 heterodimeric. There are three putative SMR family transport systems encoded in the genome 442 of B. cereus ATCC 14579. Two of these pumps, BC0852/BC0853 and BC4213/BC4214, are 443 predicted to function as heterodimers, since they are each encoded by two adjacent genes. 444 These two systems are homologous to the *B. subtilis* YkkCD system (Table 5). The complete 445 YkkCD transporter is a multidrug efflux pump that confers resistance to a range of antibiotics 446 447 and biocides [52]. As mentioned above BC0852/BC0853 are encoded near the blt homolog BC0855 in the *B. cereus* genome and are likely to be under similar regulatory control to this 448 pump. The third SMR efflux pump encoded by B. cereus ATCC 14579, BC0358, is likely to 449 450 function as a homologomer and is most related to NepA of Arthrobacter nicotinovorans (37% identity, 55% similarity), part of the NepAB efflux pump, and the staphylococcal QacC pump 451 (35% identity, 63% similarity). The NepAB system is predicted to export methylamine [53], 452 whereas QacC is a prototypical member of the SMR family and confers resistance to a range 453 of cationic biocides [54]. 454

455 Table 5. Putative *B. cereus* ATCC 14579 SMR efflux pumps

Locus tag	Conser	Best match name	Function(s) of best match	Top blastp hit(s) ^b
	vation ^a			
BC0358	92.9	NepA of Arthrobacter nicotinovorans	probably exports methylamine	Q8GAI5 2.A.7.1.8 (2e-20); P14319 2.A.7.1.1(6e-20); Q2FD83 2.A.7.1.11 (1e-18)
BC0852	93.5	YkkC of Bacillus subtilis	Multidrug efflux	P49856 2.A.7.1.5 (1e-14); D5CES3 2.A.7.1.10 (2e-13); P69937 2.A.7.1.4 (3e-12)
BC0853	92.3	YkkD of Bacillus subtilis	Multidrug efflux	P49857 2.A.7.1.5 (7e-21); D5CES3 2.A.7.1.10 (3e-20); P69937 2.A.7.1.4 (1e-17)
BC4213	88.2	YkkC of Bacillus subtilis	Multidrug efflux	P49856 2.A.7.1.5 (4e-27); D5CES3 2.A.7.1.10 (1e-22); P69937 2.A.7.1.4 (3e-21
BC4214	95.3	YkkD of Bacillus subtilis	Multidrug efflux	P49857 2.A.7.1.5 (4e-32); D5CES3 2.A.7.1.10 (4e-27); P69937 2.A.7.1.4 (6e-25)

a. Numbers show the percent conservation of the protein in the predicted proteomes of 169 *B. cereus* group isolates according to comparative BLASTP

457 searches (see Fig 1).

b. Uniprot accession numbers, TCDB accession numbers (boldface font) and e-values (in parentheses) for the top three blastp hits (e-value < 1e-5).

460 Multidrug and toxic compound extrusion family efflux pumps 461 encoded in *B. cereus* ATCC 14579

The MATE family of multidrug efflux pumps is one of 31 families classified within 462 the multidrug/oligosaccharidyl-lipid/polysaccharide flippase superfamily. Transport proteins 463 classified within the MATE family are ubiquitous to all classes of living organisms and are 464 energised by secondary energy sources, including the proton- or sodium-motive-force. The 465 genome of B. cereus ATCC 14579 encodes four putative MATE family efflux pumps, 466 BC1184, BC1383, BC1615 and BC1716, each of which is conserved in more than 98 % of 467 the *B. cereus* group strains to have had their genome sequences determined (Fig 1). None of 468 469 the *B. cereus* ATCC 14579 MATE pumps have been functionally characterised. The pump encoded by BC1716 is very similar (75% identity, 89% similarity) to the putative multidrug 470 efflux system, YoeA from B. subtilis (Table 6). The pump encoded by BC1615 is related to 471 DinF from Bacillus halodurans (31% identity, 56% similarity). DinF is multidrug efflux 472 pump that was recently characterised by X-ray crystallography, providing details of the 473 474 substrate binding site and proton coupling mechanism [55]. The BC1615 pump may also act as a multidrug efflux pump and recognise similar substrates to DinF, including the 475 antimicrobial dyes ethidium and rhodamine 6G [55]. 476

477 Table 6. Putative *B. cereus* ATCC 14579 MATE efflux pumps

Locus tag	Conser	Best match name	Function(s) of best match	Top blastp hit(s) ^b
	vation ^a			
BC1184	99.4	NorM of Thermotoga maritima	Probable multidrug resistance	Q9WZS2 2.A.66.1.28 (8e-44); P76352 2.A.66.1.23 (2e-37); D5CJ69 2.A.66.1.22 (5e-32)
BC1383	98.2	PdrM of Streptococcus pneumoniae	Multidrug efflux	Q8DPQ6 2.A.66.1.41 (1e-100); Q9I3Y3 2.A.66.1.12 (2e-97); O82855 2.A.66.1.1 (5e-95)
		DinF-like pump of Bacillus	Multidrug efflux	
BC1615	98.8	halodurans		Q9KAX3 2.A.66.1.32 (1e-67); Q7WZ38 2.A.66.1.37 (2e-64); Q93HR7 2.A.66.1.7 (3e-50)
BC1716	98.8	YoeA of Bacillus subtilis	Probable multidrug resistance	O34474 2.A.66.1.25 (0); Q2G140 2.A.66.1.13 (3e-33); I6L8P4 2.A.66.1.33 (4e-33)

a. Numbers show the percent conservation of the protein in the predicted proteomes of 169 *B. cereus* group isolates according to comparative BLASTP
 479 searches (see Fig 1).

b. Uniprot accession numbers, TCDB accession numbers (boldface font) and e-values (in parentheses) for the top three blastp hits (e-value < 1e-5).

482 Large scale qRT-PCR analyses to examine potential physiological 483 functions of efflux pumps in *B. cereus* ATCC 14579

To experimentally characterise the efflux functions of pumps identified in our in silico 484 analyses, we have constructed a number of gene deletion mutants. To date we have made 485 targeted deletions in three genes encoding MFS pumps, BC4707 [23], BC3310 [33] and 486 BC4000, all four genes encoding RND pumps, BC 0714, BC1291, BC4405 [49] and BC5435, 487 as well as BC1360 and BC0852, which encode components of an ABC pump and an SMR 488 pump, respectively. The construction of *B. cereus* gene deletion mutants is labour intensive 489 and this work identified drug resistance phenotypes for only two of the targeted pumps 490 [23,33], possibly because of functional redundancy between sub-sets of pumps encoded in B. 491 cereus, due to overlapping substrate specificities. Furthermore, a loss-of-function screen for 492 reduced biofilm formation among deletion mutants in transporters included in this study 493 identified BC4405 as the only transporter with an identifiable phenotype (S2 Fig), in line with 494 the role of SecDF in protein secretion, and the importance of cell surface proteins in *B. cereus* 495 group biofilm formation. To assess the potential transport functions of putative efflux systems 496 in B. cereus with increased throughput, we adopted an alternative approach based on gene 497 expression. 498

Most efflux pumps are only required by bacterial cells at specific times, e.g., when their substrates reach a threshold level in the cell, and the uncontrolled expression of efflux pumps at other times could reduce cellular fitness. Consequently, efflux pump expression can be tightly controlled in response to substrate or substrate-related environmental stress conditions. This inducible regulatory control offers a potential mechanism to gain insight into the core physiological functions of efflux pumps by evaluating transcriptional responses to putative substrates by qRT-PCR. To this end, we evaluated the expression of 30 efflux system genes in *B. cereus* ATCC 14579 after exposure to panel of nine antimicrobials or stress
conditions. The efflux systems tested included all three SMR family (Table 5), all four MATE
family (Table 6) and all four RND superfamily (Table 4) pumps identified in this strain, as
well as, 13 MFS (Table 2) and six ABC superfamily pumps (Table 3).

Of the eight compounds tested, five were antibiotics belonging to different drug 510 classes that are likely to be transported by efflux pumps, i.e., chloramphenicol, norfloxacin, 511 kanamycin, erythromycin and tetracycline. The antimicrobial dye ethidium bromide was 512 513 included as it is a common substrate for multidrug efflux pumps. The iron-chelating compound 2,2'-dipyridyl (DIP) was included to promote iron limitation and highlight efflux 514 systems that may be involved in iron homeostasis. Tannic acid, a polyphenolic plant derived 515 516 compound was included as an environmental compound with antimicrobial properties. 517 Finally, an extract from the cuticle of the common paper wasp *Polistes humilis*, shown to have antimicrobial activity [24], was included. This wasp extract is likely to contain a mixture of 518 519 antimicrobial compounds produced by the insect to provide microbial defence. The susceptibility of *B. cereus* ATCC 14579 towards the compounds was determined (S3 Table), 520 and the cells treated with concentrations 50% of their respective minimum inhibitory 521 concentrations (MIC). 522

We conducted hierarchical clustering to identify compounds that induced similar expression responses among the genes, and conversely sub-sets of genes that showed similar patterns of expression in response to the different antimicrobials (Fig 2). These analyses indicated that the antibiotics, particularly kanamycin, erythromycin, chloramphenicol and tetracycline, induced similar changes in gene expression. Tannic acid and DIP also induced a similar pattern of induction across the genes tested, whereas, the gene expression changes induced by ethidium bromide were distinct from the other compounds (Fig 2).

Fig 2. Gene expression changes in response to antimicrobial and environmental shock 531 532 treatments. Relative efflux pump gene expression levels were examined using qRT-PCR on RNA extracted from B. cereus ATCC 14579 treated with antimicrobial compounds compared 533 with untreated cells. B. cereus ATCC 14579 cells were grown at 30°C in MH broth to 534 OD₆₀₀=0.8 and then treated for 20 minutes with the antimicrobial compounds 535 chloramphenicol, norfloxacin, kanamycin, erythromycin, tetracycline, ethidium bromide, 536 537 2,2'-dipyridole, tannic acid and wasp extract, at concentrations corresponding to 50% of the MIC (S3 Table). The BC1744 helicase gene was used as the reference gene to normalize the 538 data. Hierarchical clustering analysis [56] was performed on the average gene expression 539 540 values using the TIGR Multi-Experiment Viewer TMEV software [57]. The scale shows log2 541 fold-changes in gene expression between treated cells and untreated controls.

542

The plant-derived polyphenolic compound tannic acid induced the expression of a 543 number of putative efflux pump genes. As seen from our clustering analyses the gene 544 545 expression changes induced by DIP were similar to those of tannic acid, but not as strong. DIP is a strong iron-chelator, and at least some of the antimicrobial properties of tannic acid 546 are known to stem from its capacity for iron chelation [58]. Therefore, the overlapping 547 expression changes induced by these compounds are most likely to be related to iron 548 limitation in the media. A small cluster of genes was strongly induced by both of these 549 550 compounds (Fig 2). Norfloxacin, which may also bind to metal ions [59], also caused low-551 level induction of the genes in this cluster. Most prominent among the genes induced by iron limitation was BC5182, which encodes an ABC pump similar to the S. aureus multidrug 552 efflux pump Sav1866 (Table 3). In light of its induction by DIP and tannic acid, BC5182 may 553 have a role in iron uptake. In line with this hypothesis a putative binding site for the ferric 554 uptake regulator (Fur) was identified 40 nt upstream of the gene. The sequence of this Fur box 555

(TGATAATGGTTATCA) is an almost perfect match to the Fur box sequence identified in *B*. *subtilis* [60]. The gene encoding the SecDF system, BC4405, was also weakly but specifically
induced by tannic acid and DIP, which may reflect a need for the cell to re-organise its
membrane protein content during iron-limitation.

560 Some genes, including the MFS gene BC4000 and the RND pump BC0714, appeared to be upregulated as a response to most or all of the tested conditions, although the strongest 561 changes in expression were induced by different compounds (Fig 2). These genes may be 562 563 regulated as part of general stress responses and could encode multidrug efflux pumps. The transporter encoded BC4000 is a member of the DHA2 family of the MFS and is closely 564 related to the characterized multidrug efflux system Bmr3 of B. subtilis, strengthening the 565 566 hypothesis that this protein functions in multidrug efflux. Interestingly, the MFS efflux 567 system encoded by BC4707, which is also closely related to Bmr3 and was recently shown to function as a multidrug exporter [23] was not highly induced by any of the compounds tested. 568 569 Expression of this pump was induced by bile salts, but based on expression signals from this gene in both microarray data and qRT-PCR this gene is not constitutively expressed at a high 570 level in *B. cereus*. Therefore the BC4707 transport protein may have additional physiological 571 functions that are unrelated to drug efflux. 572

A number of putative efflux pump genes were responsive to tetracycline and 573 chloramphenicol exposure and fell into a single large cluster that may include antibiotic efflux 574 systems (Fig 2). Many of these genes were also induced by tannic acid, albeit to a lesser 575 extent than tetracycline (Fig 2). Notably, all three SMR family pumps, BC0358, BC0852 and 576 BC4213 fell within this antibiotic induced cluster and display very similar patterns of 577 induction by the nine treatments (Fig 2). The MFS pump BC0855 was also similarly 578 responsive to the treatments. As mentioned above genes encoding the SMR pump BC0852 579 and MFS pump BC0855 are preceded by a conserved palindromic sequence that could 580

function as a binding site for a regulatory element. A similar sequence was not present in the 581 582 upstream regions of the other two SMR genes or other similarly regulated genes, suggesting these genes are under the control of distinct regulatory elements. The largest transcriptional 583 response, giving an approximately thirty-fold increase in expression compared with the 584 untreated control, was observed for the BC0870 in response to tetracycline. BC0870 was also 585 induced by more than ten-fold in response to chloramphenicol and by approximately three-586 587 fold in response to erythromycin. This is in line with the induction of its *B. subtilis* ortholog, *yheI (bmrC)*, by ribosome targeting antibiotics (see discussion of the BC0870 promoter region 588 above), however, kanamycin did not induce high expression. 589

590 The insect gut has been postulated to constitute a natural habitat for *B. cereus* group 591 bacteria [4]. Thus, transcriptional responses for the above described transporters were 592 analysed following exposure of B. cereus ATCC 14579 to insect antimicrobial compounds in a crude ethanol surface extract of a social paper wasp, Polistes humilis [24]. The putative 593 594 ABC-transporter ATP-binding protein BC1359, which had only shown a minor response upon exposure to the other antimicrobial compounds tested (Fig 2), was the only pump gene 595 showing strong expression induction by wasp extract exposure (>20-fold induction). BC1359 596 is encoded in a cluster of four genes that each encode an ABC transporter component 597 (BC1357-BC1360). BC1357 and BC1359 encode nucleotide-binding domains that are most 598 similar to ABC-2 of Streptococcus pyogenes and SboF of Streptococcus salivarius, 599 respectively (Table 3). These nucleotide-binding domains may function with proteins encoded 600 by BC1358 and BC1360 that each have six predicted transmembrane helices, to produce a 601 complete transporter with 12 transmembrane helices and two nucleotide binding domains, 602 similar to well-characterised ABC family pumps catalysing efflux. However, BC1358 and 603 BC1360 do not display any significant similarity to characterised efflux pumps listed in the 604

TCDB (Table 3). Additionally, the BC1358 gene is not highly conserved across the *B. cereus*group (20.7 % conservation; Table 3), so may be dispensable or replaceable in many strains.

607 Based on RNA sequencing data from orthologs in B. cereus ATCC 10987, the BC1356-BC1360 cluster is likely to be co-transcribed in an operon [61]. An expanded qRT-PCR 608 609 analysis of the BC1356-BC1360 locus showed that all genes were more than 19-fold upregulated following exposure to the wasp extract (S4 Table). MIC-studies further showed 610 that Proteinase K treatment (37°C, 1 h) abolished antimicrobial activity at the maximum 611 612 concentration of wasp extract available. Polistes dominulus has been shown to synthesize two antimicrobial peptides present on the cuticle and in the venom, Dominulin A and B, 613 respectively [62]. A qRT-PCR experiment investigating the transcriptional response of the 614 615 BC1356-BC1360 genes following exposure of B. cereus ATCC 14579 to custom synthesized Dominulin B at a concentration corresponding to 50% of its MIC value (S3 Table), showed 616 that all genes in the locus were induced more than 26-fold (S4 Table). Interestingly this 617 618 presents a novel B. cereus group transporter locus which is conserved across sequenced isolates and responds to one or more antimicrobial peptides from an insect source. This pump 619 could constitute a case of export proteins potentially contributing to resistance to insect-620 derived antimicrobial peptides, a resistance type which has previously largely been attributed 621 622 to alanylation of negatively charged teichoic acids by the *dlt* locus [63].

623

624 Conclusions

Using the TransAAP we demonstrated that bacterial strains within the *B. cereus* group may devote more than 2.5 % of their protein coding potential to the production of drug efflux pumps, i.e., more than 2.5 % of the CDSs annotated in *B. thuringiensis* encode an efflux pump or part of an efflux pump (Table 1). This represents one of the largest investments in

efflux potential of any bacterial lineage. We have only just begun to unravel the functions 629 630 associated with these many efflux systems. However, most pumps were highly conserved across the *B. cereus* group (Fig 1), suggesting that they mediate core functions that may be 631 common to different species occupying a variety of niches. We suspect that a number of the 632 efflux pumps encoded by members of the B. cereus group are able to mediate the efflux of 633 drugs, either as a core function or fortuitously. However, due to their large numbers we have 634 found that the characterisation of these pumps by gene deletion analyses is challenging. The 635 work described here has highlighted putative functions for a number of pumps that warrant 636 future focussed investigations in a heterologous system or using purified protein. For 637 638 example, the BC5182 ABC pump is likely to play a role in iron homeostasis, possibly by the efflux of a siderophore, whereas BC4000 and BC0714 may represent novel multidrug efflux 639 pumps, and the BC1357-BC1360 pump may confer resistance to antimicrobial peptides. We 640 641 are particularly interested in the functional mechanisms and modes of operation of the RND superfamily pumps, such as BC0714. In Gram-negative bacteria RND efflux pumps are likely 642 to capture their substrates from the periplasm and transport them across the outer membrane, 643 however, their functional roles and mechanisms of transport in Gram-positive bacteria are 644 largely unknown. 645

646

647 Acknowledgements

This research was funded by the Norwegian Research Council (FUGE II Program,
Project ID 183421) to ABK and OAØ, an Australian National Health and Medical Research
Council Project Grant (1060895) to ITP, KAH and PJFH, and a Research Development Grant
from Macquarie University to KAH and LDHE (9201401563). Consortium collaborations
between laboratories (ABK, PJFH, ITP) are funded by the EU BacMT and ATENS initiatives.

654 **References**

1. Priest FG (1993) Systematics and ecology of Bacillus. In: Sonenshein AL, Hoch JA,

- Losick R, editors. Bacillus subtilis and other Gram-positive bacteria: American Society forMicrobiology.
- Drobniewski FA (1993) Bacillus cereus and related species. Clin Microbiol Rev 6: 324 338.
- 3. Bottone EJ (2010) Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev 23:
 382-398.
- 4. Jensen GB, Hansen BM, Eilenberg J, Mahillon J (2003) The hidden lifestyles of Bacillus
 cereus and relatives. Environ Microbiol 5: 631-640.
- 5. Doganay M, Demiraslan H (2015) Human anthrax as a re-emerging disease. Recent Pat
 Antiinfect Drug Discov 10: 10-29.
- 666 6. Bottone EJ, Levine SM, Burton R, Namdari H (2003) Unclassified Bacillus species
 667 resembling Bacillus anthracis: Potential for misdiagnosis during anthrax alert. Clinical
 668 Microbiology Newsletter 25: 49-53.
- 669 7. Hoton FM, Andrup L, Swiecicka I, Mahillon J (2005) The cereulide genetic determinants
 670 of emetic Bacillus cereus are plasmid-borne. Microbiology 151: 2121-2124.
- 671 8. Ehling-Schulz M, Fricker M, Grallert H, Rieck P, Wagner M, et al. (2006) Cereulide
- 672 synthetase gene cluster from emetic Bacillus cereus: structure and location on a mega
- virulence plasmid related to Bacillus anthracis toxin plasmid pXO1. BMC Microbiol 6:

674 20.

675	9. Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, Chute MD, et al. (2004) Identification
676	of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation
677	anthrax. Proc Natl Acad Sci U S A 101: 8449-8454.
678	10. Klee SR, Brzuszkiewicz EB, Nattermann H, Bruggemann H, Dupke S, et al. (2010) The
679	genome of a Bacillus isolate causing anthrax in chimpanzees combines chromosomal
680	properties of B. cereus with B. anthracis virulence plasmids. PLoS One 5: e10986.
681	11. Leendertz FH, Ellerbrok H, Boesch C, Couacy-Hymann E, Matz-Rensing K, et al. (2004)
682	Anthrax kills wild chimpanzees in a tropical rainforest. Nature 430: 451-452.
683	12. Helgason E, Okstad OA, Caugant DA, Johansen HA, Fouet A, et al. (2000) Bacillus
684	anthracis, Bacillus cereus, and Bacillus thuringiensisone species on the basis of genetic
685	evidence. Appl Environ Microbiol 66: 2627-2630.
686	13. Priest FG, Goodfellow M, Todd C (1988) A numerical classification of the genus
687	Bacillus. J Gen Microbiol 134: 1847-1882.
688	14. Agaisse H, Gominet M, Okstad OA, Kolsto AB, Lereclus D (1999) PlcR is a pleiotropic
689	regulator of extracellular virulence factor gene expression in Bacillus thuringiensis. Mol
690	Microbiol 32: 1043-1053.
691	15. Zwick ME, Joseph SJ, Didelot X, Chen PE, Bishop-Lilly KA, et al. (2012) Genomic
692	characterization of the Bacillus cereus sensu lato species: backdrop to the evolution of
693	Bacillus anthracis. Genome Res 22: 1512-1524.
694	16. Ahmed M, Lyass L, Markham PN, Taylor SS, Vázquez-Laslop N, et al. (1995) Two
695	highly similar multidrug transporters of Bacillus subtilis whose expression is differentially
696	regulated. Journal of Bacteriology 177: 3904-3910.
697	17. Kumano M, Fujita M, Nakamura K, Murata M, Ohki R, et al. (2003) Lincomycin
698	resistance mutations in two regions immediately downstream of the -10 region of lmr

- promoter cause overexpression of a putative multidrug efflux pump in Bacillus subtilis 699
- 700 mutants. Antimicrob Agents Chemother 47: 432-435.
- 701 18. Ohki R, Murata M (1997) bmr3, a third multidrug transporter gene of Bacillus subtilis. Journal of Bacteriology 179: 1423-1427. 702
- 19. Hassan KA, Jackson SM, Penesyan A, Patching SG, Tetu SG, et al. (2013) Transcriptomic 703
- 704 and biochemical analyses identify a family of chlorhexidine efflux proteins. Proc Natl Acad Sci U S A 110: 20254-20259. 705
- 706 20. Hassan KA, Li Q, Henderson PJF, Paulsen IT (2015) Homologs of the Acinetobacter
- baumannii Acel Transporter Represent a New Family of Bacterial Multidrug Efflux 707

Systems. mBio 6: e01982-01914. 708

- 21. Ren O, Chen K, Paulsen IT (2007) TransportDB: a comprehensive database resource for 709 cytoplasmic membrane transport systems and outer membrane channels. Nucleic Acids 710 Res 35: D274-279. 711
- 22. Lechner M, Findeiss S, Steiner L, Marz M, Stadler PF, et al. (2011) Proteinortho: 712
- detection of (co-)orthologs in large-scale analysis. BMC Bioinformatics 12: 124. 713
- 23. Simm R, Voros A, Ekman JV, Sodring M, Nes I, et al. (2012) BC4707 is a major 714
- facilitator superfamily multidrug resistance transport protein from Bacillus cereus 715
- implicated in fluoroquinolone tolerance. PLoS One 7: e36720. 716
- 717 24. Hoggard SJ, Wilson PD, Beattie AJ, Stow AJ (2011) Social complexity and nesting habits are factors in the evolution of antimicrobial defences in wasps. PLoS One 6: e21763.
- 719 25. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-
- 720 PCR. Nucleic Acids Res 29: e45.

- 26. Auger S, Krin E, Aymerich S, Gohar M (2006) Autoinducer 2 affects biofilm formation
 by Bacillus cereus. Appl Environ Microbiol 72: 937-941.
- 723 27. Wijman JG, de Leeuw PP, Moezelaar R, Zwietering MH, Abee T (2007) Air-liquid
- 724 interface biofilms of Bacillus cereus: formation, sporulation, and dispersion. Appl Environ
- 725 Microbiol 73: 1481-1488.
- 28. Paulsen IT, Brown MH, Skurray RA (1996) Proton-dependent multidrug efflux systems.
 Microbiological Reviews 60: 575-608.
- 728 29. Varela MF, Sansom CE, Griffith JK (1995) Mutational analysis and molecular modelling
- of an amino acid sequence motif conserved in antiporters but not symporters in a
- transporter superfamily. Molecular Membrane Biology 12: 313-319.
- 30. Saier MH, Jr., Reddy VS, Tamang DG, Vastermark A (2014) The transporter
 classification database. Nucleic Acids Res 42: D251-258.
- 733 31. Huang J, O'Toole PW, Shen W, Amrine-Madsen H, Jiang X, et al. (2004) Novel
- chromosomally encoded multidrug efflux transporter MdeA in *Staphylococcus aureus*.
- Antimicrob Agents Chemother 48: 909-917.
- 32. Kristoffersen SM, Ravnum S, Tourasse NJ, Okstad OA, Kolsto AB, et al. (2007) Low

concentrations of bile salts induce stress responses and reduce motility in Bacillus cereus

- 738
 ATCC 14579 [corrected]. J Bacteriol 189: 5302-5313.
- 33. Kroeger JK, Hassan K, Vörös A, Simm R, Saidijam M, et al. (2015) Bacillus cereus efflux
- protein BC3310 a multidrug transporter of the unknown major facilitator family, UMF-2.
- 741 Frontiers in Microbiology 6: 1063.
- 742 34. Hotta K, Kim CY, Fox DT, Koppisch AT (2010) Siderophore-mediated iron acquisition in
- 743 Bacillus anthracis and related strains. Microbiology 156: 1918-1925.

744	35. Bechet M, Caradec T, Hussein W, Abderrahmani A, Chollet M, et al. (2012) Structure,
745	biosynthesis, and properties of kurstakins, nonribosomal lipopeptides from Bacillus spp.
746	Appl Microbiol Biotechnol 95: 593-600.

747 36. Gelis-Jeanvoine S, Canette A, Gohar M, Caradec T, Lemy C, et al. (2016) Genetic and

functional analyses of krs, a locus encoding kurstakin, a lipopeptide produced by Bacillusthuringiensis. Res Microbiol.

- 750 37. Li X, Yang H, Zhang D, Li X, Yu H, et al. (2015) Overexpression of specific proton
- 751 motive force-dependent transporters facilitate the export of surfactin in Bacillus subtilis. J

752 Ind Microbiol Biotechnol 42: 93-103.

- 75338. Branda SS, Gonzalez-Pastor JE, Ben-Yehuda S, Losick R, Kolter R (2001) Fruiting body
- formation by Bacillus subtilis. Proc Natl Acad Sci U S A 98: 11621-11626.
- 39. Lopez D, Vlamakis H, Losick R, Kolter R (2009) Paracrine signaling in a bacterium.
 Genes Dev 23: 1631-1638.
- 40. Poole K (2000) Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria
 and the mycobacteria. Antimicrobial Agents and Chemotherapy 44: 2595-2599.
- 41. Woolridge DP, Vázquez-Laslop N, Markham PN, Chevalier MS, Gerner EW, et al. (1997)

760 Efflux of the natural polyamine spermidine facilitated by the *Bacillus subtilis* multidrug

transporter Blt. Journal of Biological Chemistry 272: 8864-8866.

- 42. Serizawa M, Sekizuka T, Okutani A, Banno S, Sata T, et al. (2010) Genomewide
- screening for novel genetic variations associated with ciprofloxacin resistance in Bacillus
- anthracis. Antimicrob Agents Chemother 54: 2787-2792.
- 43. Torres C, Galian C, Freiberg C, Fantino JR, Jault JM (2009) The YheI/YheH heterodimer
- from Bacillus subtilis is a multidrug ABC transporter. Biochim Biophys Acta 1788: 615-
- 767 622.

768	44. Galian C, Manon F, Dezi M, Torres C, Ebel C, et al. (2011) Optimized purification of a
769	heterodimeric ABC transporter in a highly stable form amenable to 2-D crystallization.
770	PLoS One 6: e19677.
771	45. Reilman E, Mars RA, van Dijl JM, Denham EL (2014) The multidrug ABC transporter
772	BmrC/BmrD of Bacillus subtilis is regulated via a ribosome-mediated transcriptional
773	attenuation mechanism. Nucleic Acids Res 42: 11393-11407.
774	46. Espinasse S, Gohar M, Lereclus D, Sanchis V (2002) An ABC transporter from Bacillus
775	thuringiensis is essential for beta-exotoxin I production. J Bacteriol 184: 5848-5854.
776	47. Espinasse S, Gohar M, Lereclus D, Sanchis V (2004) An extracytoplasmic-function sigma
777	factor is involved in a pathway controlling beta-exotoxin I production in Bacillus
778	thuringiensis subsp. thuringiensis strain 407-1. J Bacteriol 186: 3108-3116.
779	48. Muller RT, Pos KM (2015) The assembly and disassembly of the AcrAB-TolC three-
780	component multidrug efflux pump. Biol Chem 396: 1083-1089.
781	49. Voros A, Simm R, Slamti L, McKay MJ, Hegna IK, et al. (2014) SecDF as part of the
782	Sec-translocase facilitates efficient secretion of Bacillus cereus toxins and cell wall-
783	associated proteins. PLoS One 9: e103326.
784	50. Tsuge K, Ohata Y, Shoda M (2001) Gene yerP, Involved in surfactin self-resistance in
785	Bacillus subtilis. Antimicrobial Agents and Chemotherapy 45: 3566-3573.
786	51. Serizawa M, Sekiguchi J (2005) The Bacillus subtilis YdfHI two-component system
787	regulates the transcription of ydfJ, a member of the RND superfamily. Microbiology 151:
788	1769-1778.
789	52. Jack DL, Storms ML, Tchieu JH, Paulsen IT, Saier MH, Jr. (2000) A broad-specificity


multidrug efflux pump requiring a pair of homologous SMR-type proteins. Journal of

791 Bacteriology 182: 2311-2313.


- 53. Ganas P, Mihasan M, Igloi GL, Brandsch R (2007) A two-component small multidrug
 resistance pump functions as a metabolic valve during nicotine catabolism by Arthrobacter
 nicotinovorans. Microbiology 153: 1546-1555.
- 54. Paulsen IT, Brown MH, Dunstan SJ, Skurray RA (1995) Molecular characterization of the
- staphylococcal multidrug resistance export protein QacC. Journal of Bacteriology 177:
 2827-2833.
- 55. Radchenko M, Symersky J, Nie R, Lu M (2015) Structural basis for the blockade of
 MATE multidrug efflux pumps. Nat Commun 6: 7995.
- 56. Soukas A, Cohen P, Socci ND, Friedman JM (2000) Leptin-specific patterns of gene
 expression in white adipose tissue. Genes Dev 14: 963-980.
- 57. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source
 system for microarray data management and analysis. Biotechniques 34: 374-378.
- 58. Lim CK, Penesyan A, Hassan KA, Loper JE, Paulsen IT (2013) Effect of tannic acid on
- the transcriptome of the soil bacterium Pseudomonas protegens Pf-5. Appl Environ
 Microbiol 79: 3141-3145.
- 59. Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW (1992) Norfloxacin
 interaction with antacids and minerals. Br J Clin Pharmacol 33: 115-116.
- 60. Fuangthong M, Helmann JD (2003) Recognition of DNA by three ferric uptake regulator
- 810 (Fur) homologs in Bacillus subtilis. J Bacteriol 185: 6348-6357.
- 811 61. Kristoffersen SM, Haase C, Weil MR, Passalacqua KD, Niazi F, et al. (2012) Global
- 812 mRNA decay analysis at single nucleotide resolution reveals segmental and positional
- degradation patterns in a Gram-positive bacterium. Genome Biol 13: R30.

814	62. Turillazzi S, Mastrobuoni G, Dani FR, Moneti G, Pieraccini G, et al. (2006) Dominulin A
815	and B: two new antibacterial peptides identified on the cuticle and in the venom of the
816	social paper wasp Polistes dominulus using MALDI-TOF, MALDI-TOF/TOF, and ESI-
817	ion trap. J Am Soc Mass Spectrom 17: 376-383.
818	63. Abi Khattar Z, Rejasse A, Destoumieux-Garzon D, Escoubas JM, Sanchis V, et al. (2009)
819	The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial
820	peptides and for virulence in insects. J Bacteriol 191: 7063-7073.
821	
822	









824 Supporting Information

825 S1 Fig. Amino acid sequence alignment of *Bacillus* RND efflux proteins with the
826 prototypical RND transporter AcrB from *E. coli*. The amino acids composing a loop likely
827 to represent the exit site for substrates from AcrB (into TolC) is marked by a red box.

S2 Fig. Biofilm formation of *B. cereus* ATCC 14579 wild type and the isogenic *AsecDF* 828 deletion mutant measured in a microplate screening assay after 48h and 72h growth. (A) 829 Bars represent the mean of four independent experiments and error bars represent the standard 830 deviation. The B. cereus ATCC 14579 wild type is shown in dark grey and the $\Delta secDF$ 831 mutant in light grey. The single star symbolizes P < 0.05 and double stars symbolize P <832 0.005 in a two-tailed paired t-test. (B) Pictures show dye-stained biofilms of wild type B. 833 cereus ATCC 14579 (B1) and $\Delta secDF$ (B2) strains after 48 h growth. Displayed is a top-834 down view of the wells, which shows a strong effect of *secDF* deletion on the submerged part 835 836 of the biofilm at the bottom of the wells. Visually there was no difference in biofilm mass between the wild type and the $\Delta secDF$ mutant for biofilm formed in the air-liquid-interface. 837

838 S1 Table. *Bacillus cereus* group strains used for comparative analyses of *B. cereus* 839 ATCC 14579 efflux pumps. A complete list of the 168 *B. cereus* group strains used in 840 comparative analyses of efflux pumps, along with the RefSeq accession numbers of their 841 genome sequences.

842 S2 Table. List of primers used in the current study. The names and nucleotide sequences843 of all primers used in the current study.


844 S3 Table. Susceptibility of *B. cereus* ATCC 14579 towards compounds used in 845 antimicrobial exposure experiments. The minimum inhibitory concentrations of the 846 compound used in transcriptional analyses against *B. cereus* ATCC 14579.


- 847 S4 Table. Expression induction of genes BC1356-BC1360 in response to wasp surface
- ethanol extract and Dominulin B. Relative expression of the BC1356-BC1360 gene cluster
- following to wasp surface ethanol extract and the antimicrobial peptide Dominulin B.

S1 Fig.

TerP HEI BC0714	
TerP VE BC0714 IE	
329	
TerP VK BC0714 HK	
493	
TerP LP BC0714 LP	SCHWEIGENPERATETYALTENALARLUMYETYYNARAUL MEROBURYT UREFHEIANYR LLAWAR HET IT SHALLANG AN YFFYYT HERBEL AT YM FFYYD HERBELARAB AR RUBWYN FFYD GAEDD Mawrael ar ffar far far far far far far far far
657	
TerP AD BC0714 AQ	
821	
TerP DE BC0714 EN	
985	
BC5435 NA TerP NA BC0714 NA	THE LIBERT AND A THE ALL REAL REAL REAL REAL REAL REAL REAL







в

1 S1 Table. *Bacillus cereus* group strains used for comparative analyses of *B. cereus* 2 ATCC 14579 efflux pumps.

ATCC 14579 ef	A		
Assembly acession	Organism name	Infraspecific name	Isolate
GCF_000742315.1	Bacillus anthracis	strain=Smith 1013	
GCF_000742695.1	Bacillus anthracis	strain=delta Sterne	
GCF_000742875.1	Bacillus anthracis	strain=BFV	
GCF_000808075.1	Bacillus anthracis	strain=A0157	NR-1041
GCF_000831505.1	Bacillus anthracis		Pollino
GCF_001277955.1	Bacillus anthracis	strain=Larissa	
GCF_000725325.1	Bacillus anthracis	strain=HYU01	
GCF_000742655.1	Bacillus anthracis	strain=2000031021	
GCF 000830095.1	Bacillus anthracis	strain=Ames A0462	NR-411
GCF_000832425.1	Bacillus anthracis	strain=PAK-1	
GCF 000832445.1	Bacillus anthracis	strain=Vollum 1B	
GCF 000832465.1	Bacillus anthracis	strain=K3	
GCF 000832505.1	Bacillus anthracis	strain=Ohio ACB	
GCF 000832565.1	Bacillus anthracis	strain=SK-102	
GCF 000832585.1	Bacillus anthracis	strain=Pasteur	
GCF 000832665.1	Bacillus anthracis	strain=BA1015	
GCF 000832725.1	Bacillus anthracis	strain=BA1035	
GCF 000832745.1	Bacillus anthracis	strain=RA3	
GCF 000832965.1	Bacillus anthracis	strain=2002013094	
GCF 000833065.1	Bacillus anthracis	strain=Ames BA1004	_
GCF 000833125.1	Bacillus anthracis	strain=Canadian Bison	A0369
GCF 000875715.1	Bacillus anthracis	strain=A1144	110505
GCF 001543225.1	Bacillus anthracis	strain=Stendal	
GCF 001654475.1	Bacillus anthracis	strain=Tangail-1	
GCF 001683065.1	Bacillus anthracis	strain=Parent2	
GCF_001683095.1	Bacillus anthracis	strain=Parent1	
GCF_001683095.1	Bacillus anthracis	strain=PR01	
GCF_001683155.1	Bacillus anthracis	strain=PR02	
GCF_001683175.1	Bacillus anthracis	strain=PR05	
GCF_001683195.1	Bacillus anthracis	strain=PR06	
GCF_001683195.1	Bacillus anthracis		
GCF_001683235.1	Bacillus anthracis	strain=PR07	
		strain=PR08	
GCF_001683255.1	Bacillus anthracis	strain=PR09-1	
GCF_001683275.1	Bacillus anthracis	strain=PR09-4	
GCF_001683295.1	Bacillus anthracis	strain=PR10-4	
GCF_000559005.1	Bacillus anthracis 52-G	strain=52-G	
GCF_000558965.1	Bacillus anthracis 8903-G	strain=8903-G	
GCF_000558985.1	Bacillus anthracis 9080-G	strain=9080-G	
GCF_000008445.1	Bacillus anthracis str. 'Ames Ancestor'	strain=Ames Ancestor	
GCF_000022865.1	Bacillus anthracis str. A0248	strain=A0248	
GCF_000512835.1	Bacillus anthracis str. A16	strain=A16	
GCF_000512775.1	Bacillus anthracis str. A16R	strain=A16R	
GCF_000007845.1	Bacillus anthracis str. Ames	strain=Ames	
GCF_000021445.1	Bacillus anthracis str. CDC 684	strain=CDC 684	
GCF_000258885.1	Bacillus anthracis str. H9401	strain=H9401	
GCF_000008165.1	Bacillus anthracis str. Sterne	strain=Sterne	
GCF_000832635.1	Bacillus anthracis str. Sterne	strain=Sterne	
GCF_000583105.1	Bacillus anthracis str. SVA11	strain=SVA11	
GCF_000833275.1	Bacillus anthracis str. Turkey32	strain=Turkey32	
GCF_000832785.1	Bacillus anthracis str. V770-NP-1R	strain=V770-NP-1R	
GCF_000742895.1	Bacillus anthracis str. Vollum	strain=Vollum	
GCF_000635895.2	Bacillus cereus	strain=A1	
GCF_000789315.1	Bacillus cereus	strain=03BB87	
GCF_000832525.1	Bacillus cereus	strain=FM1	
GCF_000832765.1	Bacillus cereus	strain=3a	

GCF 000835185.1	Bacillus cereus	strain=S2-8	
GCF 000978375.1	Bacillus cereus	strain=FORC 005	chicken
			cutlett
GCF_001277915.1	Bacillus cereus	strain=NJ-W	
GCF_001518875.1	Bacillus cereus	strain=FORC_013	
GCF_001635915.1	Bacillus cereus	strain=CMCC P0021	
GCF_001635955.1	Bacillus cereus	strain=CMCC P0011	
GCF_001635995.1	Bacillus cereus	strain=HN001	
GCF_000022505.1	Bacillus cereus 03BB102	strain=03BB102	
GCF_000832405.1	Bacillus cereus 03BB102	strain=03BB102	
GCF_000832865.1	Bacillus cereus 03BB108	strain=03BB108	
GCF_000160935.1	Bacillus cereus 172560W	strain=172560W	
GCF_000161135.1	Bacillus cereus 95/8201	strain=95/8201	
GCF_000161375.1	Bacillus cereus AH1271	strain=AH1271	
GCF_000161395.1	Bacillus cereus AH1272	strain=AH1272	
GCF_000003955.1	Bacillus cereus AH1273	strain=AH1273	
GCF_000021225.1	Bacillus cereus AH187	strain=AH187	
GCF_000161335.1	Bacillus cereus AH603	strain=AH603	
GCF_000160975.1	Bacillus cereus AH621	strain=AH621	
GCF_000161355.1	Bacillus cereus AH676	strain=AH676	
GCF_000021785.1	Bacillus cereus AH820	strain=AH820	
GCF_000160895.1	Bacillus cereus ATCC 10876	strain=ATCC 10876	
GCF_000008005.1	Bacillus cereus ATCC 10987	strain=ATCC 10987	
*GCF_000007825.1	Bacillus cereus ATCC 14579	strain=ATCC 14579	
GCF_000161015.1	Bacillus cereus ATCC 4342	strain=ATCC 4342	
GCF_000832845.1	Bacillus cereus ATCC 4342	strain=ATCC 4342	
GCF_000021205.1	Bacillus cereus B4264	strain=B4264	
GCF_000161115.1	Bacillus cereus BDRD-Cer4	strain=BDRD-Cer4	
GCF_000161095.1	Bacillus cereus BDRD-ST196	strain=BDRD-ST196	
GCF_000161055.1	Bacillus cereus BDRD-ST24	strain=BDRD-ST24	
GCF_000161075.1	Bacillus cereus BDRD-ST26	strain=BDRD-ST26	
GCF_000160915.1	Bacillus cereus BGSC 6E1	strain=BGSC 6E1	
GCF_000143605.1	Bacillus cereus biovar anthracis str. CI	strain=CI	
GCF_000832385.1	Bacillus cereus D17	strain=D17	
GCF_000011625.1	Bacillus cereus E33L	strain=E33L	
GCF_000833045.1	Bacillus cereus E33L	strain=E33L	
GCF_000338315.1	Bacillus cereus F	strain=F	
GCF 000161315.1	Bacillus cereus F65185	strain=F65185	
GCF_000239195.1	Bacillus cereus F837/76	strain=F837/76	
GCF_000292415.1	Bacillus cereus FRI-35	strain=FRI-35	
GCF 000832805.1	Bacillus cereus G9241	strain=G9241	
GCF_000021305.1	Bacillus cereus G9842	strain=G9842	
GCF 000003645.1	Bacillus cereus m1293	strain=m1293	
GCF_000161035.1	Bacillus cereus m1550	strain=m1550	
GCF 000160955.1	Bacillus cereus MM3	strain=MM3	
GCF 000283675.1	Bacillus cereus NC7401		
GCF 000013065.1	Bacillus cereus Q1	strain=Q1	
GCF 000160995.1	Bacillus cereus R309803	strain=R309803	
GCF 000161175.1	Bacillus cereus Rock1-15	strain=Rock1-15	
GCF 000161155.1	Bacillus cereus Rock1-3	strain=Rock1-3	
GCF_000161195.1	Bacillus cereus Rock3-28	strain=Rock3-28	
GCF_000161215.1	Bacillus cereus Rock3-29	strain=Rock3-29	
GCF 000161235.1	Bacillus cereus Rock3-42	strain=Rock3-42	
GCF 000161255.1	Bacillus cereus Rock3-44	strain=Rock3-44	
GCF 000161295.1	Bacillus cereus Rock4-18	strain=Rock4-18	
GCF 000161275.1		strain=Rock4-2	
GCF_000161275.1 GCF_000017425.1	Bacillus cereus Rock4-2	strain=Rock4-2 strain=NVH 391-98	
GCF_000161275.1 GCF_000017425.1 GCF_000742855.1		strain=Rock4-2 strain=NVH 391-98 strain=219298	

GCF 000003925.1	Bacillus mycoides DSM 2048	strain=DSM 2048
GCF 000161415.1	Bacillus mycoides Rock1-4	strain=Rock1-4
GCF 000161435.1	Bacillus mycoides Rock3-17	strain=Rock3-17
GCF 000161455.1	Bacillus pseudomycoides DSM 12442	strain=DSM 12442
GCF 000832485.1	Bacillus thuringiensis	strain=HD1011
GCF 000832825.1	Bacillus thuringiensis	strain=HD571
GCF 000832925.1	Bacillus thuringiensis	strain=HD682
GCF 000833085.1	Bacillus thuringiensis	strain=97-27
GCF 001017635.1	Bacillus thuringiensis	strain=YC-10
GCF 001182785.1	Bacillus thuringiensis	strain=HS18-1
GCF 001420855.1	Bacillus thuringiensis	strain=YWC2-8
GCF_001455345.1	Bacillus thuringiensis	strain=CTC
GCF_001595725.1	Bacillus thuringiensis	strain=Bt185
GCF_001598095.1	Bacillus thuringiensis	strain=HD12
GCF_001618665.1	Bacillus thuringiensis	strain=Bc601
GCF_001685565.1	Bacillus thuringiensis	strain=MYBT18246
GCF_001692675.1	Bacillus thuringiensis	strain=KNU-07
GCF_000092165.1	Bacillus thuringiensis BMB171	strain=BMB171
GCF_000161495.1	Bacillus thuringiensis Bt407	strain=Bt407
GCF_000306745.1	Bacillus thuringiensis Bt407	
GCF_000342025.1	Bacillus thuringiensis DAR 81934	strain=DAR 81934
GCF_000292455.1	Bacillus thuringiensis HD-771	strain=HD-771
GCF_000292705.1	Bacillus thuringiensis HD-789	strain=HD-789
GCF_000835025.1	Bacillus thuringiensis HD1002	strain=HD1002
GCF_000161715.1	Bacillus thuringiensis IBL 200	strain=IBL 200
GCF_000161735.1	Bacillus thuringiensis IBL 4222	strain=IBL 4222
GCF_000300475.1	Bacillus thuringiensis MC28	strain=MC28
GCF_001640965.1	Bacillus thuringiensis serovar alesti	strain=BGSC 4C1
GCF_000161635.1	Bacillus thuringiensis serovar andalousiensis BGSC 4AW1	strain=BGSC 4AW1
GCF_000161615.1	Bacillus thuringiensis serovar berliner ATCC 10792	strain=ATCC 10792
GCF_000193355.1	Bacillus thuringiensis serovar chinensis CT-43	
GCF_000190515.1	Bacillus thuringiensis serovar finitimus YBT- 020	
GCF_000803665.1	Bacillus thuringiensis serovar galleriae	strain=4G5
GCF_000161675.1	Bacillus thuringiensis serovar huazhongensis BGSC 4BD1	strain=BGSC 4BD1
GCF_001183785.1	Bacillus thuringiensis serovar indiana	strain=HD521
GCF_000008505.1	Bacillus thuringiensis serovar konkukian str. 97-27	strain=97-27
GCF_000835235.1	Bacillus thuringiensis serovar kurstaki	strain=HD 1i
GCF_000717535.1	Bacillus thuringiensis serovar kurstaki str. HD- 1	strain=HD-1
GCF_000338755.1	Bacillus thuringiensis serovar kurstaki str. HD73	strain=HD73
GCF_000161575.1	Bacillus thuringiensis serovar kurstaki str. T03a001	strain=T03a001
GCF_000688795.1	Bacillus thuringiensis serovar kurstaki str. YBT-1520	strain=YBT-1520
GCF_000747545.1	Bacillus thuringiensis serovar kurstaki str. YBT-1520	strain=YBT-1520
GCF_000161595.1	Bacillus thuringiensis serovar monterrey BGSC 4AJ1	strain=BGSC 4AJ1
GCF_000940785.1	Bacillus thuringiensis serovar morrisoni	strain=serovar morrisoni BGSC 4AA1
GCF_000161555.1	Bacillus thuringiensis serovar pakistani str. T13001	strain=T13001
GCF_000161655.1	Bacillus thuringiensis serovar pondicheriensis BGSC 4BA1	strain=BGSC 4BA1
GCF_000161695.1	Bacillus thuringiensis serovar pulsiensis BGSC 4CC1	strain=BGSC 4CC1

GCF_000341665.1	Bacillus thuringiensis serovar thuringiensis str. IS5056	strain=IS5056
GCF_000161515.1	Bacillus thuringiensis serovar thuringiensis str. T01001	strain=T01001
GCF_000161475.1	Bacillus thuringiensis serovar tochigiensis BGSC 4Y1	strain=BGSC 4Y1
GCF_001548175.1	Bacillus thuringiensis serovar tolworthi	
GCF_000015065.1	Bacillus thuringiensis str. Al Hakam	strain=Al Hakam
GCF_000832885.1	Bacillus thuringiensis str. Al Hakam	strain=Al Hakam
GCF_000497525.1	Bacillus thuringiensis YBT-1518	strain=YBT-1518
GCF_000775975.1	Bacillus weihenstephanensis	strain=WSBC10204
GCF_000018825.1	Bacillus weihenstephanensis KBAB4	strain=KBAB4

* *B. cereus* ATCC 14579 was used as the reference isolate. The table incudes relevant information from the NCBI RefSeq assembly summary table.

Forward primer	Sequence 5' to 3'	Reverse primer	Sequence 5' to 3'
BC0256_MFS_F	cagetgcatcagetatggte	BC0256_MFS_R	ccaatcgcagcacctatatt
BC0434_MFS_F	tatgctcgttatggcgtctg	BC0434_MFS_R	accggatcattattcgttcg
BC0667_MFS_F	tatctggtgctgctgttgga	BC0667_MFS_R	cgatcgtaccaagagccatt
BC0855_MFS_F	ggattaatcattccggttatgc	BC0855_MFS_R	ccatcggcctgtaataggtg
BC1681_MFS_F	gcattaacttcgtctattccgagt	BC1681_MFS_R	aaccatatacaactccgccaat
BC1786_MFS_F	tatcgccaatatggggaaag	BC1786_MFS_R	acaaaccccataagcgtcat
BC2230_MFS_F	aagagagtggaggagagacaaca	BC2230_MFS_R	ccgattccttcgttacatagc
BC2894_MFS_F	cttggcacaggcttcttctt	BC2894_MFS_R	gcagattgcgaatgctgtt
BC3212_MFS_F	tggtgatgatgccacttatga	BC3212_MFS_R	gtaccaatggaaccggacac
BC3310_MFS_F	aaacatggatcacgacgaca	BC3310_MFS_R	accgtactgcacagtgcttg
BC4000_MFS_F	tttgtttgggtcacatcagc	BC4000_MFS_R	gaaaagaatgaggccaccaa
BC4568_MFS_F	gatgatgacaggtcgcgtaa	BC4568_MFS_R	cgtttatgaggcgggaataa
BC4707_MFS_F	acggaaagctcgctgattta	BC4707_MFS_R	gcgcggaagaagattaattg
BC0852_SMR_F	cggagctggtacggtaggta	BC0852_SMR_R	aaccgataacgccagctaca
BC0358_SMR_F	aagetegttecaagtgtaetga	BC0358_SMR_R	taatgttccaacgccagacc
BC4213_SMR_F	agcagaggcaccacttgaat	BC4213_SMR_R	accageteegatteetgtaa
BC1383_MATE_F	ctattgcagctcaccaagca	BC1383_MATE_R	gctccaacttcgaatccaac
BC1615_MATE_F	aataccagccgttcttggaa	BC1615_MATE_R	atgetggaatagecaegtte
BC1716_MATE_F	gctcggtattccagcgagta	BC1716_MATE_R	cttgattcacaacgccgtaa

1 S2 Table. List of primers used in the current study

BC1184_MATE_F	gctcgcaatgaacttacaagg	BC1184_MATE_R	acggataattgcggctaatg
BC0714_RND_F	accgagctgccattatcatc	BC0714_RND_R	tgtgacggtaattgctggatt
BC1291_RND_F	agatgcttcgcatgaggaat	BC1291_RND_R	gccgatgtcatcttgtagca
BC4405_RND_F	cgtgtacagcttgctggtgt	BC4405_RND_R	ccgttccatccataagaagg
BC5435_RND_F	caatgattggtgcgcttatg	BC5435_RND_R	cgtgttgcaccagcttctaa
BC1356_F	ccctctgtccgtgaattagc	BC1356_R	taccgtcccattcctctacg
BC1357_ABC_F	tgtccgataagccaatctttg	BC1357_ABC_R	aaattetgeaategtatetaceg
BC1358_ABC_F	caggagttagaatttcaggtaggc	BC1358_ABC_R	tttccgaaaagacgatatacctg
BC1359_ABC_F	aagagcgcattgctgagatt	BC1359_ABC_R	atgcagtaatgcctgtgcaa
BC1360_ABC_F	gttgaagtggggaaaaggtg	BC1360_ABC_R	aagagtacgggcagcaagtg
BC5285_ABC_F	ggaccgagtggatctggtaa	BC5285_ABC_R	tcgatgctacttggtcctgt
BC0509_ABC_F	caaggaatgcaagtgacacg	BC0509_ABC_R	aatgttcttgccgtccaact
BC0870_ABC_F	gtacggaagcagcgatcatt	BC0870_ABC_R	actgcgccttcatccataac
BC5182_ABC_F	gctcacagacttgcaacgat	BC5182_ABC_R	tactgtatcctccgccttgc
BC5433_ABC_F	ttagcaggtgaacacgttgg	BC5433_ABC_R	gtgtccattctacgcgacct
helicase_F	cgagaaaagaaactgcccata	helicase_R	gctctgcttgaattccatctg

1 S3 Table. Susceptibility of *B. cereus* ATCC 14579 towards compounds used in

Substance	Class/comment	MIC
Chloramphenicol	Phenicol antibiotic	2.5 µg/ml*
Norfloxacin	Quinolone antibiotic	2.5 µg/ml
Kanamycin	Aminoglycoside antibiotic	15 µg/ml*
Erythromycin	Macrolide antibiotic	0.2 µg/ml*
Tetracycline	Tetracycline antibiotic	2.5 µg/ml*
Ethidium bromide	Antimicrobial dye, common MD efflux pump substrate	40 µg/ml*
2,2'-dipyridol	Iron chelator	1 mM
Tannic acid	Plant derived polyphenol, iron chelator	40 µg/ml
Dominulin B	Insect derived antimicrobial peptide	16 µg/ml

2 antimicrobial exposure experiments

3 * The MIC was previously determined [23].

1 S4 Table. Expression induction of genes BC1356-BC1360 in response to wasp surface

2 ethanol extract and Dominulin B.

Gene	Relative expression following	Relative expression following exposure
	wasp surface ethanol extract	of cells to Dominulin B
	exposure	
BC1356	19.4 (+/- 2.2)	81.4 (+/- 2.4)
BC1357	22.4 (+/- 1.7)	67.8 (+/- 2.2)
BC1358	27.9 (+/- 1.3)	48.4 (+/- 1.6)
BC1359	23.2 (+/- 1.7)	26.1 (+/- 2.2)
BC1360	20.4 (+/- 1.5)	26.8 (+/- 1.9)

3 * Expression was normalised to that of the BC1744 helicase gene, and the relative expression

4 shown is the geometric mean of three independent experiments. The standard deviation

5 indicated in parentheses is the geometric standard deviation.